

ARTHRITIS & RHEUMATISM

OFFICIAL JOURNAL OF THE AMERICAN RHEUMATISM ASSOCIATION
SECTION OF THE ARTHRITIS FOUNDATION

CONTENTS VOLUME 22, 1979

VOLUME 22

JANUARY

NO. 1

T _γ Cells in Systemic Lupus Erythematosus: Variation with Disease Activity <i>Maurice E. Hamilton and John B. Winfield</i>	1
Significance of Serum C-Reactive Protein Elevation in Patients with Systemic Lupus Erythematosus <i>Nazih Zein, Carlos Ganuza, and Irving Kushner</i>	7
Demonstration of β ₁ H Globulin Together with C3 in the Dermal-Epidermal Junction of Patients with Systemic Lupus Erythematosus <i>Jaime R. Carlo, Naomi F. Rothfield, and Shaun Ruddy</i>	13
Survey for Immune Complexes in Disseminated Gonococcal Arthritis-Dermatitis Syndrome <i>Charles L. Ludivico and Allen R. Myers</i>	19
Radiologic Analysis of Arthritis in Rats after Systemic Injection of Streptococcal Cell Walls <i>Richard L. Clark, John T. Cuttino, Jr., Sonia K. Anderle, William J. Cromartie, and John H. Schwab</i>	25
Serum Amyloid A Protein in Amyloidosis, Rheumatic, and Neoplastic Diseases <i>Merrill D. Benson and Alan S. Cohen</i>	36
Articular Manifestations of Mixed Connective Tissue Disease <i>Francisco Ramos-Niembro, Donato Alarcón-Segovia, and Jorge Hernández-Ortiz</i>	43
Effects of Estrogen on Cartilage and Experimentally Induced Osteoarthritis <i>Itzhak A. Rosner, Victor M. Goldberg, Lee Getzy, and Roland W. Moskowitz</i>	52
PHA-Induced Cellular Cytotoxicity: Inhibition by a Nonimmunoglobulin Factor Present in Sera from Patients with Active Systemic Lupus Erythematosus <i>Alejandro Ruiz-Argüelles, Efrain Díaz-Jouanen, and Donato Alarcón-Segovia</i>	59
Histologic Assessment of Lymphokine-Mediated Suppression of Chondrocyte Glycosaminoglycan Synthesis <i>Michael S. Taplits, John D. Crissman, and Jerome H. Herman</i>	66
Case Report: Lymphocytes from Synovial Tissue of a Boy with X-Linked Hypogammaglobulinemia and Chronic Polyarthritis <i>Tore G. Abrahamsen, Stig S. Frøland, Erik Kåss, Jacob B. Natvig, and Jan Pahle</i>	71
Case Report: Tarsal Tunnel Syndrome with Ankylosing Spondylitis <i>Tobias Enright, George C. Liang, Theodore A. Fox, and Roland F. Mueller</i>	77
Coexistent Gout and Rheumatoid Arthritis: Case Report and Literature Review <i>Daniel J. Wallace, James R. Klinenberg, Daniel Morhaim, Bruce Berlanstein, Pamela C. Biren, and Gilbert Callis</i>	81
Current Comment: Antibodies Reacting with Ribosomal Ribonucleoprotein in Connective Tissue Diseases <i>Kiyomitsu Miyachi and Eng M. Tan</i>	87
Letters.....	94
ARA Announcements.....	104

Long-Term Chrysotherapy in Rheumatoid Arthritis <i>Ramachandran Srinivasan, Bruce L. Miller, and Harold E. Paulus</i>	105
Alpha-1-Antitrypsin Phenotypes in Rheumatoid Arthritis and Systemic Lupus Erythematosus <i>Jacob Karsh, John Vergalla, and E. Anthony Jones</i>	111
Immunofluorescence Studies of Anti-T Cell Antibodies and T Cells in Systemic Lupus Erythematosus: Selective Loss of Brightly Staining T Cells in Active Disease <i>Alfred D. Steinberg, Lynell W. Klassen, Daniel R. Budman, and Gary W. Williams</i>	114
Differential Sensitivity of Functional Subsets of T Cells to the Cytotoxicity of Natural T-Lymphocytotoxic Autoantibody of Systemic Lupus Erythematosus <i>Takao Koike, Seiichi Kobayashi, Takashi Yoshiki, Tetsuo Itoh, and Toshikazu Shirai</i>	123
Skin Thickness and Collagen Content in Progressive Systemic Sclerosis and Localized Scleroderma <i>Gerald P. Rodnan, Esther Lipinski, and Joan Luksick</i>	130
Detection of Intermediate Complexes by Evaluation of the Difference Between γ -Globulin and IgG Concentrations <i>Francis A. Nardella, Bruce C. Gilliland, and Mart Mannik</i>	141
Ribavirin Treatment in Murine Autoimmune Disease. I. Therapeutic Efficacy and Effect on the Immune Response <i>Lynell W. Klassen, Gary W. Williams, James L. Reinertsen, N. Lynn Gerber, and Alfred D. Steinberg</i>	145
Cartilage Proteoglycan Alterations in an Experimentally Induced Model of Rabbit Osteoarthritis <i>Roland W. Moskowitz, David S. Howell, Victor M. Goldberg, Ofelia Muniz, and Julio C. Pita</i>	155
Joint Effusions after Kidney Transplantation <i>John D. MacFarlane, Ronald S. Filo, and Kenneth D. Brandt</i>	164
Synovitis in Secondary Syphilis: Clinical, Light, and Electron Microscopic Studies <i>Antonio J. Reginato, H. Ralph Schumacher, Sergio Jimenez, and Kenneth Maurer</i>	170
Reflex Sympathetic Dystrophy Syndrome of the Knee Following Meniscectomy: Report of Three Cases <i>Hong Joon Kim, Franklin Kozin, Roger P. Johnson, and Robert Hines</i>	177
Arthritis Rounds: Rheumatoid Arthritis, Amyloidosis, and Chylous Effusions <i>Sanford Baim, Cecil O. Samuelson, and John R. Ward</i>	182
Discussion <i>Edgar S. Cathcart</i>	186
The Training of United States Rheumatologists, 1927-1976: Description and Evaluation of the Training Experience <i>Curtis J. Henke and Wallace V. Epstein</i>	187
Brief Reports	197
Letters	201
Book Review	208

Increased Toxoplasma Antibodies in Idiopathic Inflammatory Muscle Disease: A Case-Controlled Study <i>Paul E. Phillips, Stuart S. Kassan, and Lawrence J. Kagen</i>	209
Long Term Effectiveness of Low Dose Mithramycin for Paget's Disease of Bone <i>A. S. Russell, I. M. Chalmers, J. S. Percy, and B. C. Lentle</i>	215
Detection of Low Avidity Anti-DNA Antibodies in Systemic Lupus Erythematosus <i>Richard L. Riley, Hugh McGrath, Jr., and Ronald P. Taylor</i>	219
Anti-dsDNA and Complement Profiles as Prognostic Guides in Systemic Lupus Erythematosus <i>A. J. G. Swaak, L. A. Aarden, L. W. Statius Van Eps, and T. E. W. Feltkamp</i>	226
Alteration of Lymphocyte Function in NZB/NZW Mice. IV. Response to Levamisole <i>Bevra H. Hahn and Linda L. Knotts</i>	236
Immunoelectrophoretic Assay for Synovial Fluid C3 with Correction for Synovial Fluid Globulin <i>Peter Hasselbacher</i>	243

Inhibition of Collagen Gelation by Action of the Superoxide Radical <i>Robert A. Greenwald and Wai W. Moy</i>	251
Connective Tissue Activation. XIV. Composition and Actions of a Human Platelet Autacoid Mediator <i>C. William Castor, James C. Ritchie, Charles H. Williams, Jr., Mary E. Scott, Sherry L. Whitney, Stephen L. Myers, Tod B. Sloan, and Byron E. Anderson</i>	260
Atlantoaxial Subluxation as a Complication of Early Ankylosing Spondylitis: Two Case Reports and a Review of the Literature <i>Steven Sorin, Ali Askari, and Roland W. Moskowitz</i>	273
Case Report: Unusual Electromyographic Findings in a Patient with Polymyalgia Rheumatica <i>Milton D. Gross, Mark H. Borkin, and Stephen Rupp</i>	277
Case Report: Apparent Acute Renal Failure Associated with Therapeutic Aspirin and Ibuprofen Administration <i>Robert P. Kimberly, Raymond L. Sherman, Janet Mouradian, and Michael D. Lockshin</i>	281
Case Report: The Kniest (Swiss Cheese Cartilage) Syndrome: Description of a Distinct Arthropathy <i>Rida Frayha, Rafic Melhem, and Hassan Idriss</i>	286
Current Comment: Rheumatology: What Should Students Know? <i>Cecil O. Samuelson, Jr., Thomas W. Cockayne, and H. James Williams</i>	290
Arthritis Rounds: Acute Monocytic Arthritis <i>Arthur E. Brawer and Edgar S. Cathcart</i>	294
Discussion <i>Allen C. Steere</i>	300
Brief Reports.....	302
Book Review.....	307
Letters.....	308
ARA Announcements.....	311

VOLUME 22

APRIL

NO. 4

An Antineuronal Antibody Cross-Reacting with Erythrocytes and Lymphocytes in Systemic Lupus Erythematosus <i>Barry Bresnihan, Mary Oliver, Bryan Williams, and Graham R. V. Hughes</i>	313
Anti-Native DNA Detection by the <i>Crithidia Luciliae</i> Method: An Improved Guide to the Diagnosis and Clinical Management of Systemic Lupus Erythematosus <i>Stanley P. Ballou and Irving Kushner</i>	321
Frequency of Systemic Lupus Erythematosus in Different Ethnic Groups in Hawaii <i>Mary K. Serdula and George G. Rhoads</i>	328
Therapeutic Effect of Prolonged Hyperbaric Oxygen in Adjuvant Arthritis of the Rat <i>Joel Warren, Miriam R. Sacksteder, and Claire A. Thuning</i>	334
Comparative Antiinflammatory and Bone Protective Effects of Two Diphosphonates in Adjuvant Arthritis <i>Lawrence Flora</i>	340
Collagen-Induced Arthritis in Rats: Comparison of Vitreous and Cartilage-Derived Collagens <i>John M. Stuart, Michael A. Cremer, Saryu N. Dixit, Andrew H. Kang, and Alexander S. Townes</i>	347
Interaction of Polymorphonuclear Leukocytes with Immune Complexes Trapped in Joint Collagenous Tissues <i>Kazuhiro Ugai, Morris Ziff, and Hugo E. Jasin</i>	353
Epidemiology of Ankylosing Spondylitis in Rochester, Minnesota, 1935-1973 <i>Earl T. Carter, Charles H. McKenna, Dana D. Brian, and Leonard T. Kurland</i>	365
HLA-D Locus Typing in Ankylosing Spondylitis and Reiter's Syndrome <i>Kip Kemple, Richard A. Gatti, Wolfgang Leibold, James Klinenberg, and Rodney Bluestone</i>	371
Comparison of Gastrointestinal Effects of Aspirin and Fenoprofen: A Double-Blind Crossover Study <i>Stanley M. Chernish, Bernard D. Rosenak, Rocco L. Brunelle, and Ross Crabtree</i>	376
Steady-State Serum Salicylate Levels in Hospitalized Patients with Rheumatoid Arthritis: Comparison of Two Dosage Schedules of Choline Magnesium Trisalicylate <i>Sidney Cassell, Daniel Furst, Sydney Dromgoole, and Harold Paulus</i>	384

Identification of Hydroxyapatite Crystals in Synovial Fluid <i>Paul B. Halverson and Daniel J. McCarty</i>	389
Idiopathic Edema as a Cause on Nonarticular Rheumatism <i>Robert S. Pinals, Theodore G. Dalakas, and David H. P. Streeten</i>	396
Studies on Vaccine-Induced Rubella Arthritis: Serologic Findings Before and After Immunization <i>Aubrey J. Tingle, G. D. M. Kettys, and Denys K. Ford</i>	400
Deposition of β 1H Globulin in Kidneys of Patients with Immune Renal Disease <i>Jaime R. Carlo, Shaun Ruddy, Suzanne Sauter, and William J. Yount</i>	403
Immunoregulation in New Zealand Mice. I. Failure of the Transfer of Syngeneic Spleen or Thymus Cells to Influence the Natural Disease in New Zealand Mice <i>Andree A. Hoffman and Ronald J. Harbeck</i>	412
Case Report: Factor XII Deficiency with Systemic Lupus Erythematosus: Biological Implications <i>Frank C. Passero, Allen R. Myers, and DuPont Guerry</i>	419
Brief Reports	423
Letters	427
Book Review	431
ARA Announcements	432

VOLUME 22

MAY

NO. 5

Comparison of Three Immunoassays for Immune Complexes in Rheumatoid Arthritis <i>Ramesh C. Gupta, Frederic C. McDuffie, Kent A. Huston, Gerhard Tappeiner, Michael Meurer, Robert E. Jordan, Harvinder S. Luthra, Gene G. Hunder, and Duane Ilstrup</i>	433
Immune Complexes in Rheumatoid Arthritis Sera and Synovial Fluids: A Comparison of Three Methods <i>James T. Halla, John E. Volanakis, and Ralph E. Schrohenloher</i>	440
Central Nervous System Lupus Erythematosus: Measurement of Cerebrospinal Fluid Cyclic GMP and Other Clinical Markers of Disease Activity <i>Stuart S. Kassan and Lawrence J. Kagen</i>	449
Association of IgG Anti-Brain Antibodies with Central Nervous System Dysfunction in Systemic Lupus Erythematosus <i>H. Alexander Wilson, John B. Winfield, Robert G. Lahita, and David Koffler</i>	458
Studies on the Specificity and Clinical Correlation of Antiribosomal Antibodies in Systemic Lupus Erythematosus Sera <i>David Koffler, Thomas E. Miller, and Robert G. Lahita</i>	463
Lyme Arthritis: Correlation of Serum and Cryoglobulin IgM with Activity, and Serum IgG with Remission <i>Allen C. Steere, John A. Hardin, Shawn Ruddy, Jon G. Mummaw, and Stephen E. Malawista</i>	471
Circulating Immune Complexes in Mixed Connective Tissue Disease <i>James T. Halla, John E. Volanakis, and Ralph E. Schrohenloher</i>	484
Increased Antibody-Dependent Cell-Mediated Cytotoxicity by Monocytes from Patients with Rheumatoid Arthritis <i>Paul H. Waytz and Steven D. Douglas</i>	490
Long Term Chrysotherapy: Incidence of Toxicity and Efficacy During Sequential Time Periods <i>W. F. Kean and T. P. Anastasiades</i>	495
The Immunologic and Clinical Associations of the Split Products of C3 in Plasma in Juvenile Rheumatoid Arthritis <i>John J. Miller III, Yao-Pi Hsu, Richard Moss, Kerttu Kelomaa-Sulonen, Cara L. Osborne, and Lynne Olds-Arroyo</i>	502
Development and Reversal of a Proteoglycan Aggregation Defect in Normal Canine Knee Cartilage After Immobilization <i>Marshall Palmoski, Elaine Perricone, and Kenneth D. Brandt</i>	508
Cardiopulmonary Manifestations of Progressive Systemic Sclerosis: Associations with Circulating Immune Complexes and Fluorescent Antinuclear Antibodies <i>Edward Pisko, Kenneth Gallup, Robert Turner, Michael Parker, Abdel-Moshem Nomeir, Jane Box, John Davis, Pat Box, and Henry Rothberger</i>	518
Purine Nucleoside Phosphorylase Deficiency: Biochemical Properties and Heterogeneity in Two Families <i>Robert L. Wortmann, Catherine Andres, Janice Kaminska, Edwin Mejias, Erwin Gelfand, William Arnold, Kenneth Rich, and Irving H. Fox</i>	524
Scleroderma after Cosmetic Surgery: Four Cases of Human Adjuvant Disease <i>Yasuo Kumagai, Chiyuki Abe, and Yuichi Shiokawa</i>	532

Special Article: Arthritis on Stamps <i>Robert A. Greenwald</i>	538
Case Report: Congenital Contractural Arachnodactyly: Description of a New Kindred <i>Raymond T. Mirise and Stuart Shear</i>	542
Case Report: Synovial Fat Necrosis Associated with Ischemic Pancreatic Disease <i>Nathan M. Smukler, H. Ralph Schumacher, Eliseo Pascual, Sylvan Brown, William E. Ryan, and M. Reza Sadeghain</i>	547
Brief Reports	
Systemic Lupus Erythematosus and Amyloidosis <i>Susana Webb, Fernando Segura, Francisco Cervantes, Alejandro Darnell, Eladio Soriano, Manuel Ribas-Mundo, and Juan Garcia-San Miguel</i>	554
Quantitation of Antibodies to Extractable Nuclear Antigens (ENA) by Hemagglutination: A Useful Modification <i>Joanna L. Schaefer and Ralph E. Schrohenloher</i>	557
Musculoskeletal Manifestations of Addison's Disease <i>Leonard H. Calabrese and Constance S. White</i>	558
Definitive Diagnosis of Gout by Identification of Urate Crystals in Asymptomatic Metatarsophalangeal Joints <i>Carlos A. Agudelo, Abraham Weinberger, H. Ralph Schumacher, Robert Turner, and Javier Molina</i>	559

VOLUME 22

JUNE

NO. 6

Cardiac Involvement in Rheumatoid Arthritis: Followup Study <i>Abdel Mohsen Nomeir, Robert A. Turner, and Lester E. Watts</i>	561
IgG Antibodies to Double-Stranded DNA in Systemic Lupus Erythematosus Sera: Independent Variation of Complement Fixing Activity and Total Antibody Content <i>Andre Beaulieu, Francisco P. Quismorio, Jr., George J. Friou, Bharathi Vayuvegula, and Gary Mirick</i>	565
C3 Activation by Monosodium Urate Monohydrate and Other Crystalline Material <i>Peter Hasselbacher</i>	571
Acute Metabolic Effects of Nitrogen Mustard and Thiotepa on Rabbit Articular Cartilage and Synovium <i>Henry J. Mankin and Louis Lippiello</i>	579
Proceedings of the 43rd Annual Meeting of the American Rheumatism Association: Abstracts of Papers Presented	586
Brief Reports	
Complete Heart Block in Mixed Connective Tissue Disease <i>Woodruff Emlen</i>	679
Pseudopodagra from <i>Hemophilus Influenza</i> in an Adult <i>William M. McClatchey and John A. Goldman</i>	681
Takayasu's Arteritis: Association with Still's Disease in an Adult <i>Wendell A. Wilson, Owen S. Morgan, B. Bain, and Joy E. Taylor</i>	684

VOLUME 22

JULY

NO. 7

Synovial Permeability in Rheumatoid Arthritis <i>Peter A. Simkin with the technical assistance of Joseph E. Pizzorno</i>	689
Increased Clq Binding Immune Complexes in Felty's Syndrome: Comparison with Uncomplicated Rheumatoid Arthritis <i>Eric R. Hurd, Andrew Chubick, Hugo E. Jasin, and Morris Ziff</i>	697
Plasmapheresis and Lymphoplasmapheresis in the Management of Rheumatoid Arthritis <i>Daniel J. Wallace, Dennis Goldfinger, Richard Gatti, Cheryl Lowe, Peng Fan, Rodney Bluestone, and James R. Klinenberg</i>	703
Arthritis Associated with Jejunoileal Bypass: Clinical and Immunologic Evaluation <i>Merle Zapanta, Marlene Aldo-Benson, Angenieta Biegel, and James Madura</i>	711
Clearance of Calcium Pyrophosphate Dihydrate Crystals in Vivo. I. Studies Using ¹⁶⁹ Yb Labeled Triclinic Crystals <i>Daniel J. McCarty, David W. Palmer, and Paul B. Halverson</i>	718

The Phlogistic Potential of Urate in Solution: Studies of the Phagocytic Process in Human Leukocytes <i>Stephen E. Malawista, Gretchen Van Blaricom, Stella B. Cretella, and Morris L. Schwartz</i>	728
Urate Binding to Serum Albumin: Lack of Influence on Renal Clearance of Uric Acid <i>Edward W. Holmes and P. Blondet</i>	737
Cellular Immunity in Polymyalgia Rheumatica and Giant Cell Arteritis: Lack of Response to Muscle or Artery Homogenates <i>Christos C. Papaioannou, Gene G. Hunder, and Frederic C. McDuffie</i>	740
Effects of Salicylate on Proteoglycan Metabolism in Normal Canine Articular Cartilage in Vitro <i>Marshall J. Palmoski and Kenneth D. Brandt</i>	746
Chemotactic Factor-Induced Generation of Superoxide Radicals by Human Neutrophils: Effect of Metabolic Inhibitors and Antiinflammatory Drugs <i>Louis Simchowitz, Jagdish Mehta, and Isaias Spilberg</i>	755
Mortality in Lupus Nephritis <i>Jacob Karsh, John H. Klippel, James E. Balow, and John L. Decker</i>	764
Studies of Immune Functions of Patients with Systemic Lupus Erythematosus. III. Characterization of Lymphocyte Subpopulations Responsible for Defective Autologous Mixed Lymphocyte Reactions <i>Tsuyoshi Sakane, Alfred D. Steinberg, Frank C. Arnett, James L. Reinertsen, and Ira Green</i>	770
Drug Acetylation Phenotype Unrelated to Development of Spontaneous Systemic Lupus Erythematosus <i>Richard J. Morris, Curt R. Freed, and Peter F. Kohler</i>	777
Case Report: The Arthropathy of Fabry Disease <i>Kumudachandra J. Sheth and Gerson C. Bernhard</i>	781
Case Report: Ankylosing Spondylitis and Multiple Sclerosis: A Possible Association <i>Muhammad A. Khan and Irving Kushner</i>	784
Current Comment: Continuing Education in Rheumatoid Arthritis for the Primary Care Physician <i>Jeffrey K. Stross and Giles G. Bole</i>	787
Brief Reports	
Elastofibroma: A Rare Cause of Periscapsular Pain <i>Pamela Prete and Roger P. Thorne</i>	792
Resolution of the Identity of Certain Antigen-Antibody Systems in Systemic Lupus Erythematosus and Sjögren's Syndrome: An Interlaboratory Collaboration <i>Margaret Alspaugh and Peter Maddison</i>	796
Disappearing Lumbar Hyperostosis in a Patient with Forestier's Disease: An Ominous Sign <i>Abe Chaiton, Adel Fam, and Bruce Charles</i>	799
Letters	803
ARA Announcements	807

VOLUME 22

AUGUST

NO. 8

An Evaluation of Salivary Scintigraphy in Sjögren's Syndrome <i>Troy E. Daniels, Malcolm R. Powell, Robert A. Sylvester, and Norman Talal</i>	809
The Clinical Significance of Raynaud's Phenomenon in Systemic Lupus Erythematosus <i>Jacob Dimant, Ellen Ginzler, Michael Schlesinger, Gary Sterba, Herbert Diamond, David Kaplan, and Max Weiner</i>	815
Polyarteritis Nodosa in Childhood: A Clinical Pathologic Study <i>Robert E. Ettlinger, Audrey M. Nelson, Edmund C. Burke, and J. T. Lie</i>	820
Pharmacokinetic Monitoring of Salicylate Therapy in Children with Juvenile Rheumatoid Arthritis <i>Lauren M. Pachman, Richard Olufs, Josephine A. Procknal, and Gerhard Levy</i>	826
Ophthalmologic Safety of Long-Term Hydroxychloroquine Treatment <i>Richard I. Rynes, Gregory Krohel, Anthony Falbo, Robert D. Reinecke, Bruce Wolfe, and Lee E. Bartholomew</i>	832
Quantitative Sacroiliac Joint Scintigraphy: A Critical Assessment <i>George Ho, Jr., Nicholas Sadovnikoff, Chander M. Malhotra, and Ben C. Claunch</i>	837

Search for Epstein-Barr and Type C Oncornaviruses in Systemic Lupus Erythematosus <i>John T. Hicks, Gurmit S. Aulakh, Philip P. McGrath, Glennelle C. Washington, Elizabeth Kim, and F. Paul Alepa</i>	845
Deposition of Antibodies to a Soluble Cytoplasmic Antigen in the Kidneys of Patients with Systemic Lupus Erythematosus <i>Peter J. Maddison and Morris Reichlin</i>	858
Simultaneous Immunologic Studies of Skin and Kidney in Systemic Lupus Erythematosus: Clinicopathologic Correlations <i>Richard J. Morris, Stephen J. Guggenheim, Rawle M. McIntosh, Robert L. Rubin, and Peter F. Kohler</i>	864
Glycosaminoglycan Synthesis and Glucose Uptake by Rheumatoid and Nonrheumatoid Fibroblastic Cells in Culture: The Effect of Nutritional Factors <i>Tassos P. Anastasiades, Janice Ley, and Anne Wood</i>	871
A Tissue Culture Model of Cartilage Breakdown in Rheumatoid Arthritis. III. Effects of Antirheumatic Drugs <i>James Steinberg, Soichiro Tsukamoto, and Clement B. Sledge</i>	877
Quantification of Human Plasma Inorganic Pyrophosphate. I. Normal Values in Osteoarthritis and Calcium Pyrophosphate Dihydrate Crystal Deposition Disease <i>Lawrence M. Ryan, Franklin Kozin, and Daniel J. McCarty</i>	886
Quantification of Human Plasma Inorganic Pyrophosphate. II. Biologic Variables <i>Lawrence M. Ryan, Franklin Kozin, and Daniel J. McCarty</i>	892
Platelet Aggregation and Aggregation Inhibition by Different Antiglobulins and Antiglobulin Complexes from Sera of Patients with Rheumatoid Arthritis <i>P. C. Fink, U. Piening, M. Fricke, and H. Deicher</i>	896
A Syndrome Resembling Progressive Systemic Sclerosis after Bone Marrow Transplantation: A Model for Scleroderma? <i>Daniel E. Furst, Philip J. Clements, Peter Graze, Robert Gale, and Nigel Roberts</i>	904
Immunoblastic Sarcoma with Features of Sjögren's Syndrome and Systemic Lupus Erythematosus in a Patient with Immunoblastic Lymphadenopathy <i>Donald A. Pierce, Robert Stern, Ronald Jaffe, Jules Zulman, and Norman Talal</i>	911
Current Comment: A Review of the Use, Evaluations, and Criticisms of the Preliminary Criteria for the Classification of Systemic Lupus Erythematosus <i>Juan J. Canoso and Alan S. Cohen</i>	917
Brief Reports	
Management of Rheumatoid Arthritis with Oral Gold <i>Michael H. Weisman and Denise M. Hannifin</i>	922
Apparent Vasculitis Associated with Propylthiouracil Use <i>Brian D. Houston, Michael E. Crouch, James E. Brick, and Anthony G. DiBartholomeo</i>	925
HLA Antigens in Chondrocalcinosis and Ankylosing Chondrocalcinosis <i>Anonito J. Reginato, Virgilio Schiapachasse, Chester M. Zmijewski, H. Ralph Schumacher, Cecilia Fuentes, and Monica Galdamez</i>	928
Primary Amyloidosis Resembling Sicca Syndrome <i>Barry G. Simon and Haralampos M. Moustopoulos</i>	932
Letters	935
Journal Budget	942
ARA Announcements	943

VOLUME 22

SEPTEMBER

NO. 9

Does Corticosteroid Therapy Affect the Survival of Patients with Systemic Lupus Erythematosus? <i>Daniel A. Albert, Nordin M. Hadler, and Marian W. Ropes</i>	945
Serum Complement Abnormalities in the Antinuclear Antibody-Positive Relatives of Children with Systemic Lupus Erythematosus <i>Thomas J. A. Lehman, Virgil Hanson, Bernhard H. Singsen, Helen K. Kornreich, Bram Bernstein, and Karen K. King</i>	954
Reassessment of the Clinical Significance of Native DNA Antibodies in Systemic Lupus Erythematosus <i>Michael F. Minter, B. David Stollar, and Vincent Agnello</i>	959

Antigenic Bacterial Polysaccharide in Rheumatoid Synovial Effusions <i>Lee E. Bartholomew and Frances N. Bartholomew</i>	969
T Lymphocyte Subpopulations in Synovial Fluid of Patients with Rheumatic Disease <i>Gunnel Biberfeld, Ethel Nilsson, and Peter Biberfeld</i>	978
Increase in Fibronectin in the Deep Dermis of Involved Skin in Progressive Systemic Sclerosis <i>Sheldon M. Cooper, Anthony J. Keyser, Andre D. Beaulieu, Erkki Ruoslahti, Marcel E. Nimni, and Francisco P. Quismorio, Jr.</i>	983
IgG Rheumatoid Factor: Relationship to Seropositive Rheumatoid Arthritis and Absence in Seronegative Disorders <i>Richard M. Pope and Sandra J. McDuffy</i>	988
The Rarity of Felty's Syndrome in Blacks <i>Trudy Elsmore Termini, Joseph J. Biundo, Jr., and Morris Ziff</i>	999
Early Complement Component Depletion and Mixed Cryoglobulinemia in a "Healthy" Family <i>John R. Waterman, Jerry A. Winkelstein, Ronald N. Berzofsky, Susan H. Hsu, Wilma B. Bias, and Frank C. Arnett</i>	1006
Case Reports	
Mutilans-Like Arthropathy in Mixed Connective Tissue Disease <i>Donato Alarcón-Segovia and Oscar Uribe-Uribe</i>	1013
Glomerulonephritis in Rheumatoid Arthritis <i>James A. Davis, Arthur H. Cohen, Richard Weisbart, and Harold E. Paulus</i>	1018
Hypocomplementemic Urticarial Vasculitis with Glomerulonephritis and Pseudotumor Cerebri <i>Charles L. Ludivico, Allen R. Myers, and Kenneth Maurer</i>	1024
Special Article: A Uniform Database for Rheumatic Diseases <i>The Computer Committee of the American Rheumatism Association</i>	1029
Brief Reports	
Regular and Enteric Coated Aspirin: A Reevaluation <i>J. Javier Orozco-Alcala and John Baum</i>	1034
Use of Thermography in the Diagnosis of Plant Thorn Synovitis <i>John F. Schenck and James M. Strosberg</i>	1037
Clostridia Discitis: A Case Report <i>David Pate and Arnold Katz</i>	1039

VOLUME 22

OCTOBER

NO. 10

Rheumatology 1979—Art, Achievements, and Problems: Presidential Address to the American Rheumatism Association <i>Alan S. Cohen</i>	1041
Lymphocyte Depletion by Continuous Flow Cell Centrifugation in Rheumatoid Arthritis: Clinical Effects <i>Jacob Karsh, Daniel G. Wright, John H. Klippel, John L. Decker, Albert B. Deisseroth, and M. Wayne Flye</i>	1055
Lymphocytotoxic Antibodies in Systemic Lupus Erythematosus and Clinically Related Diseases <i>Alan L. Schocket and Peter F. Kohler</i>	1060
Erythrocyte Rosette Inhibition as an Assay for Naturally Occurring T Lymphocytotoxic Antibody in Systemic Lupus Erythematosus <i>Takao Koike, Seiichi Kobayashi, Takashi Yoshiki, Tetsuo Itoh, and Toshikazu Shirai</i>	1064
Serum-Serum Interactions in Autoimmune Mice <i>Robert A. Eisenberg, Lee T. Thor, and Frank J. Dixon</i>	1074
Arthritis after Frostbite Injury in Children <i>Guillermo F. Carrera, Franklin Kozin, and Daniel J. McCarty</i>	1082
Cardiac Involvement in Polymyositis: A Clinicopathologic Study of 20 Autopsied Patients <i>Charles E. Denbow, J. T. Lie, Robert G. Tancredi, and Thomas W. Bunch</i>	1088
Articular Cartilage Preservation and Storage. I. Application of Tissue Culture Techniques to the Storage of Viable Articular Cartilage <i>Carl T. Brighton, Chester A. Shadle, Sergio A. Jimenez, John T. Irwin, Joseph M. Lane, and Mitchel Lipton</i>	1093

Articular Cartilage Preservation and Storage. II. Mechanical Indentation Testing of Viable, Stored Articular Cartilage	
Jonathan Black, Chester A. Shadle, John Russell Parsons, and Carl T. Brighton.....	1102
Collagenase Production by Synovial Fibroblasts Treated with Phorbol Myristate Acetate	
Constance E. Brinckerhoff, Rodger M. McMillan, John V. Fahey, and Edward D. Harris, Jr.....	1109
In Vitro Hexosamine Depletion of Intact Articular Cartilage by E-Prostaglandins: Prevention by Chloroquine	
John P. Fulkerson, Inge-Maria Ladenbauer-Bellis, and O. Donald Chrisman.....	1117
Clearance of Calcium Pyrophosphate Dihydrate Crystals in Vivo. II. Studies Using Triclinic Crystals Doubly Labeled with ⁴⁵ Ca and ⁸⁵ Sr	
Daniel J. McCarty, David W. Palmer, and Christopher James.....	1122
Case Reports	
Renal Involvement in Progressive Systemic Sclerosis: Prolonged Survival with Aggressive Antihypertensive Management	
Joseph A. Markenson and Raymond L. Sherman.....	1132
A Circulating Anticoagulant Directed against Factor XIa in Systemic Lupus Erythematosus	
Charles A. DiSabatino, Lionel P. Clyne, and Stephen E. Malawista.....	1135
Brief Reports	
Arthritis Due to <i>Listeria Monocytogenes</i>	
James H. Newman, Sandra Waycott, and Leo M. Cooney, Jr.	1139
Reiter's Syndrome after Salmonella Infection: Occurrence in HLA-B27 Positive Brothers	
Michael B. Jones, Philip W. Smith, and Ronald W. Olnhausen.....	1141
Intraarticular Microfilariae in Laboratory Animals	
Abraham Weinberger, H. Ralph Schumacher, and David J. Weiner.....	1142
Limited Plasmapheresis in Rheumatoid Arthritis with Vasculitis	
John A. Goldman, Helen L. Casey, Harris McIlwain, Jacqueline Kirby, Colon H. Wilson, Jr., and Stephen B. Miller	1146
ARA Announcements.....	1151

VOLUME 22

NOVEMBER

NO. 11

Proceedings of the Kroc Foundation Conference on Sex Factors, Steroid Hormones, and the Host Response.....	1153-1320
--	-----------

VOLUME 22

DECEMBER

NO. 12

A Controlled Study of Pneumococcal Polysaccharide Vaccine in Systemic Lupus Erythematosus	
John H. Klippel, Jacob Karsh, Neil I. Stahl, John L. Decker, Alfred D. Steinberg, and Gerald Schiffman .	1321
Infection in Patients with Systemic Lupus Erythematosus: Association with a Serum Inhibitor of Complement-Derived Chemotactic Activity	
H. Daniel Perez, Richard I. Andron, and Ira M. Goldstein	1326
Identification of a Clinical Subset of Systemic Lupus Erythematosus by Antibodies to the SM Antigen	
Donna M. Winn, J. Frederick Wolfe, Donald A. Lindberg, Frank H. Fristoe, Larry Kingsland, and Gordon C. Sharp	1334
Accelerated Appearance of Neoplasms in Female NZB/NZW Mice Treated with High-Dose Cyclophosphamide	
Sara E. Walker and Miriam R. Anver	1338
Collagen-Induced Arthritis in Rats: Evaluation of Early Immunologic Events	
John M. Stuart, Michael A. Cremer, Andrew H. Kang, and Alexander S. Townes.....	1344
Gold-Induced Changes in the Morphology and Functional Capabilities of Human Monocytes	
Kazuhiro Ugai, Morris Ziff, and Peter E. Lipsky	1352
Reaction of Superficial Bursae in Response to Specific Disease Stimuli	
Juan J. Canoso and Robert A. Yood.....	1361
Effects of Naproxen on Connective Tissue Changes in the Adjuvant Arthritic Rat	
N. R. Ackerman, W. H. Rooks, II, L. Shott, H. Genant, P. Maloney, and E. West.....	1365

Future Research Directions: Mycoplasma Infections as Models of Chronic Joint Inflammation <i>Barry C. Cole and Gail H. Cassell</i>	1375
Current Comment: Central Nervous System Lupus Erythematosus: The Need for Classification <i>Stuart S. Kassin and Michael D. Lockshin</i>	1382
Case Reports	
Chronic Tenosynovial Hand Infection From <i>Mycobacterium Terrae</i> <i>James T. Halla, John S. Gould, and Joe G. Hardin</i>	1386
Hemarthrosis Associated with Glanzmann's Thrombasthenia <i>Raymond W. Kloforn and Alton L. Lightsey</i>	1390
Editorial: The American Rheumatism Association and The Arthritis Foundation: Commentary on 14 Years of a Happy Union <i>Daniel J. McCarty</i>	1394
Brief Reports	
A Lupus Antibody Syndrome Associated with Hypernephroma <i>Robert M. Marcus and Arthur I. Grayzel</i>	1396
Danazol's Failure to Suppress Autoimmunity in NZB/NZW F ₁ Mice <i>Jirayr R. Roubinian, Norman Talal, John S. Greenspan, Joseph R. Goodman, and Victor Nussenzweig</i>	1399
Universal Sarcoid Dactylitis: A Case Report <i>Solomon Forouzes, Peng Thim Fan, and Rodney Bluestone</i>	1403
The Effect of Thoracic Duct Drainage on Lymphocyte Dynamics and Clinical Symptoms in Patients with Rheumatoid Arthritis <i>Toyoyi Ueo, Seisuke Tanaka, Yoshinori Tominaga, Hiroyuki Ogawa, and Takehiko Sakurami</i>	1405
Letters	
Measurement of Anti-dsDNA <i>Charles R. Steinman</i>	1413
Reply <i>A. J. G. Swaak, L. W. Statius van Eps, T. E. W. Feltkamp, and L. A. Aarden</i>	1414
Cost Containment in Carpal Tunnel Syndrome <i>Stanley J. Alexander</i>	1415
Polymorphonuclear Cell Interactions with Immune Complexes in Cartilage <i>T. Derek V. Cooke and Masaho Maeda</i>	1416
Pseudogouty Arthritis in Hypothyroidism <i>Shlomo Dux, Silvio Pitlik, and J. B. Rosenfeld</i>	1416
Reversible Proteinuria as a Complication of Oral Gold Therapy <i>Moshe Revach, Robert L. Freed, and George E. Ehrlich</i>	1417
The Half-Life of Gold Sodium Thiomalate <i>Elaine S. Waller, Joseph W. Massarella, James E. Crout, and Gerald J. Yakatan</i>	1418
Effect of Hemiparesis on Rheumatoid Arthritis <i>Richard Dean Smith</i>	1419
Psoriatic Arthritis: Results of Light and Electron Microscopy after Early and Late Synovectomy <i>K. M. Rohe, M. Bierther, and D. Wessinghage</i>	1420
The Relationship between C-Reactive Protein and Systemic Lupus Erythematosus <i>S. A. Lauter, L. R. Espinoza, and C. K. Osterland</i>	1421
Child Resistant Cap Syndrome <i>Nicolas Radoiu</i>	1422
Takayasu's Arteritis and Still's Disease <i>George Ehrlich</i>	1422
Book Reviews	1423
Contents Volume 22, 1979	1425
Indexes	1435

AUTHOR INDEX

A

Aarden LA, 226, 1414
 Abdou N, 586
 Abdullah A, 663
 Abe C, 532
 Abrahamsen TG, 71
 Ackerman NR, 1365
 Adams JP, 100
 Adelman H, 659
 Agnello V, 959
 Agudelo C, 559, 672
 Akhazrova V, 624
 Alarcon-Segovia D, 43, 59, 96, 586, 935, 1013
 Albert DA, 945
 Alcocer J, 308, 587
 Aldo-Benson M, 711
 Alepa FP, 845
 Alexander SJ, 1415
 Allen T, 599
 Alspaugh M, 587, 588, 796
 Altman R, 666
 Anastassiades T, 494, 871
 Anderle SK, 25
 Anderson BE, 260
 Anderson R, 588
 Andres C, 524
 Andron R, 646, 1326
 Anver MR, 1338
 Arbor A, 590
 Arend W, 588, 649, 662
 Arguelles A, 586
 Arnett F Jr, 589, 607, 622, 623, 655, 665, 770, 1006
 Arnold G, 615
 Arnold W, 524, 634
 Arroyave C, 609, 617
 Arthur R, 677
 Asscher A, 667
 Atkins C, 663
 Atkinson J, 590
 Aulakh GS, 845

B

Baim S, 182
 Bain B, 684
 Baker D, 590
 Baker S, 590
 Baldassare A, 639, 677
 Ball GV, 1423
 Ballou S, 321
 Balow J, 764
 Balthazar A, 937
 Balz G, 602
 Bancer L, 593
 Bankhurst A, 657
 Banks PM, 938
 Banting G, 606
 Bar R, 672
 Barada F, 591
 Bardwick P, 605
 Barth W, 610
 Bartholomew FN, 969
 Bartholomew LE, 832, 969
 Bashey R, 625
 Bassett L, 595
 Bastian D, 650
 Baum J, 1034
 Beale M, 617
 Beary J, 591
 Beaulieu A, 565, 983
 Belin D, 592
 Bell C, 592
 Bell D, 592, 593
 Bennett R, 429
 Benson MD, 36
 Bergen W, 423
 Bergstresser P, 657, 658
 Berlanstein B, 81
 Berman L, 593
 Berne B, 635
 Berney S, 427
 Bernhard G, 781
 Bernstein B, 593, 631, 633, 661, 954
 Bernstein M, 594
 Berzofsky RN, 1006
 Bethesda N, 641
 Bhatnagar R, 651
 Bias W, 589, 607, 622, 1006
 Biberfeld G, 978
 Biberfeld P, 978
 Biegel A, 711
 Bierther M, 1420
 Billingsley L, 594, 665
 Biren PC, 81
 Biundo JJ Jr, 588, 999
 Black J, 1102
 Blackman M, 657
 Blaricom G, 728
 Blau M, 651
 Block J, 592
 Blocka K, 595
 Blondet P, 737
 Bluestein H, 605
 Bluestone H, 674
 Bluestone R, 371, 431, 670, 703, 1403, 1423
 Blumberg BS, 1261, 1264
 Boegel WA, 1170, 1177
 Bole G, 787
 Bordwell B, 592
 Borel Y, 595
 Borkin MH, 277
 Bove K, 601, 602
 Box J, 518
 Box P, 518
 Boyko W, 663
 Boyse EA, 1153
 Bradlow HL, 1195
 Brandt KD, 164, 508, 644, 645, 662, 746
 Braun W, 628
 Braver AE, 294
 Bresnahan B, 313
 Brewsman S, 305

Brian D, 365
 Brick JE, 925
 Brighton CT, 1093, 1102
 Brinckerhoff C, 595, 596, 1109
 Brigham R, 588, 592
 Britton M, 671
 Brown S, 547
 Brown T, 663
 Brunelle R, 376
 Brunner C, 674
 Buckingham R, 608, 658
 Budman DR, 114
 Bunch TW, 1088
 Burch P, 429
 Burke EC, 820
 Burkholder S, 617
 Butt J, 623

C

Cabeen W, 599
 Calabro J, 596
 Calin A, 304, 425, 632, 659, 806, 939
 Callery R, 595
 Callis G, 81
 Campbell P, 597
 Campion E, 590
 Canoso J, 428, 597, 917, 1361
 Cantor H, 1153
 Carel RS, 936
 Carlo JR, 13, 403
 Carpenter JR, 103, 204
 Carrera GF, 1082
 Carter E, 365
 Casey HL, 1146
 Cassell GH, 1375
 Cassell S, 384
 Cassidy J, 602, 639
 Castles J, 611
 Castor CW, 260, 641
 Castro-Escobar LE, 302
 Cathcart ES, 186, 294
 Cervantes F, 554
 Cesarini J, 609
 Chaiton A, 799
 Chalem F, 646
 Chalker D, 634
 Chalmers IM, 215
 Chang D, 648
 Chang J, 673
 Chang L, 615
 Charles B, 799
 Cheigh J, 591, 603
 Chernish S, 376
 Chernoff D, 646
 Cheung H, 653
 Choi H, 647
 Chopra S, 604
 Chow D, 632, 643
 Chrisman OD, 1117
 Christian C, 629
 Chubick A, 697
 Chused T, 597, 640

Ciampi M, 804
 Clague R, 598
 Clark RL, 25
 Claunch BC, 837
 Cleland L, 599
 Clements P, 595, 599, 604, 904
 Clemons LE, 1300
 Clyne LP, 1135
 Cochran C, 612
 Cockayne TW, 290
 Cohen AH, 1018
 Cohen AS, 43, 653, 677, 917, 1041
 Cohen L, 672
 Cohen P, 600
 Cohn DA, 1218
 Cole B, 670, 1375

The Computer Committee
 of the American Rheumatism Association, 1029

Conaty J, 600
 Conn DL, 938
 Convery F, 601
 Convery M, 601
 Cooke T, 614, 1416
 Cooney LM Jr, 1139
 Cooper N, 612
 Cooper SM, 627, 983
 Cordoba O, 936
 Cornell C, 643, 644
 Crabtree GR, 1246
 Crabtree R, 376
 Cremer M, 347, 1344
 Cretella S, 728
 Crissman JD, 66
 Cromartie WJ, 25
 Crouch ME, 925
 Crout JE, 1418
 Crowe W, 601, 602
 Cuttino JT, 25

D

Dalakos T, 396
 Dang H, 603
 D'Angelo W, 603
 Daniak N, 659
 Daniels TE, 809
 Darnell A, 554
 Davies M, 667
 Davis JA, 604, 1018
 Davis JS, 518, 674
 Dawkins RL, 94
 Dawood M, 624
 Dayer J, 604
 DeCamargo EP, 207
 Decker J, 610, 624, 626, 640, 647, 649, 764, 1055, 1321
 DeCeulaer K, 803
 Deforest A, 614
 de Groot E, 633
 Deicher H, 896
 Deisseroth AB, 626, 1055
 DeLuca H, 672

De Medicis R, 939
Denbow CE, 1088
Dennis M, 621
Depper J, 605
Deyo R, 605
Diamond H, 605, 613, 638, 815
Diaz-Jouanen E, 59
DiBartolomeo AG, 925
Dimant J, 815
DiSabatino CA, 1135
Dixit S, 347
Dixon F, 606, 625, 1074
Dobson S, 594
Dorner R, 639
Douglas S, 490
Doury P, 310
Dove FB, 204
Dromgoole S, 384
Dunne J, 652
Duvic M, 1170
Dux S, 1416

E

Ebling F, 606
Edelstein P, 806
Edwards N, 675
Egan M, 428
Ehrlich GE, 1418, 1422
Eisenberg R, 606, 625, 1074
Emery H, 669
Emlen W, 679
Engleman E, 606
Enlow R, 607, 622
Enright T, 77
Epstein WV, 187, 607, 673, 675
Escobar-Gutierrez A, 302
Espinoza LR, 204, 1421
Eitlinger RE, 820
Evarts C, 626
Eyre D, 649

F

Fahey JV, 596, 1109
Falbo A, 832
Fam A, 799
Fan P, 670, 703, 1403
Farber S, 608, 630
Fatham C, 616
Feltkamp TEW, 226, 1414
Feichtner J, 608
Figley BA, 307
Filo RS, 164
Finch W, 608
Fink PC, 896
Finkel R, 608, 630
Fishbein E, 96
Fishman J, 633, 1195
Fitzgerald J, 645
Fleischmajer R, 609
Flora L, 340
Flye MW, 626, 1055
Ford D, 400, 663
Forstot J, 609
Forouzes S, 1403
Fox I, 524, 675
Fox TA, 77

Fraga A, 302, 308, 587
Frank M, 618, 1295
Franks J, 616
Franklin E, 618
Fraygam R, 286
Freed C, 777
Freed JF, 203
Freed RL, 1417
Freeman S, 606
Fricke M, 896
Fries JF, 632, 671, 1029
Friou G, 565
Fristoe FH, 1334
Fritzier M, 640
Froland SS, 71
Fuentes C, 928
Fulkerson JP, 1117
Furst D, 384, 595, 599, 604, 904
Fuzesi L, 637

G

Galdamez M, 928
Gale P, 806
Gale R, 904
Gallo RC, 1308
Gallop P, 634
Gallup K, 518
Ganuza C, 7
Gatti R, 371, 670, 703
Gavin S, 662
Gay S, 609
Gelfand E, 524
Genant H, 1365
George FW, 1275
Gerber D, 610
Gerber LH, 610
Gerber NL, 145
Gershwin M, 611
Gertman P, 638
Getzy L, 52
Gibbas D, 611
Gibofsky A, 646, 662
Gibson T, 645
Giclas P, 612
Gilliam J, 612, 660
Gilliland BC, 141
Gillis S, 1246
Gindhart TD, 1234
Ginsberg M, 612, 940
Ginzler E, 613, 815
Goldberg M, 622
Goldberg V, 52, 155, 613, 637
Goldfinger D, 670, 703
Goldman J, 681, 1146
Golds E, 614
Goldsmith D, 614
Goldstein I, 646, 1326
Goodman JR, 1399
Goodwin J, 614
Gorevic P, 618
Gorodezsky C, 302
Goto M, 666
Gottlieb M, 425, 632, 806
Gottlieb NL, 615
Gould JS, 1386
Gourlay R, 663

Gowans J, 615
Gru R, 616
Grayzel AI, 1396
Graze P, 904
Green F, 651
Green I, 655, 770
Green R, 940
Greenspan J, 657, 1399
Greenwald RA, 251, 538, 616
Griffin A, 645
Griffin JE, 1275
Griffin JH, 612
Griffing WL, 616
Gross MD, 277
Gudino J, 308, 587
Guerry D, 419
Guggenheim SJ, 864
Guertin M, 660
Gundberg C, 634
Gupta R, 433, 588, 617
Gutman A, 936
Gyves MT, 202

H

Hadler NM, 945
Hahn BH, 236, 306, 606, 617, 665
Halushka P, 630
Halla J, 440, 484, 1386
Halverson P, 389, 718
Hamburger M, 618
Hamilton ME, 1, 674
Hamm D, 619
Hanauer LB, 309
Hannifin DM, 922
Hanson V, 593, 631, 633, 661, 954
Hara I, 632
Harbeck R, 412, 603
Hardin J Jr, 471, 619, 662, 1386
Harmon C, 609
Harris BK, 102
Harris E Jr, 595, 596, 1109
Hasselbacher P, 243, 571, 620
Hauselman C, 602
Hawkins BR, 94
Hayakawa T, 666
Healey LA, 103, 201
Hebert J, 95
Heiple K, 613
Hendren R, 665
Henke CJ, 187, 607
Henle G, 587
Henle W, 587, 588
Herman JH, 66, 621
Hernandez-Ortiz J, 43
Herrara R, 587
Hess E, 601, 1029
Hicks JT, 845
Hicks R, 621
Hines R, 177
Hinkle SC, 202
Hirsch T, 622
Ho G, 622, 837
Hoffman A, 412
Hoffman R, 659
Hoffman W, 622

Holmes E, 737
Holt P, 598, 623
Holt S, 623
Hopkins M, 667
Hoppe R, 425, 632
Horwitz D, 591
Houston BD, 925
Howell DS, 155, 655, 666
Hrncir Z, 101
Hsu SH, 1006
Hsu Y, 502
Hughes G, 313
Hunder G, 433, 740
Hungerford D, 624
Hurd E, 657, 658, 697
Hurwitz A, 649
Hurwitz C, 650
Huston K, 433

I

Idriss H, 286
Ilstrup D, 433
Inman R, 624, 629, 643, 644
Irwin JT, 1093
Isaacs H Jr, 631
Itoh T, 123, 1064
Ivanova M, 624
Ivey K, 623
Iwata H, 1211
Izui S, 625

J

Jackson W, 636
Jaffe R, 911
Jaffray D, 806
James C, 1122
Jaques B, 612
Jasin H, 353, 697
Jayadeven K, 605
Jessee E Jr, 625
Jimenez S, 170, 625, 1093
Joachim C, 637
Johnson M, 635
Johnson RP, 177
Jones EA, 111
Jones MB, 1141
Jordon R, 433
Joseph D, 626
Joslin F, 667
Jovanovic L, 624
Julie N, 637
Jurjus A, 1308

K

Kagen LJ, 299, 449
Kaminska J, 524
Kammer G, 656
Kane M, 623
Kang A, 347, 665, 1344
Kaplan D, 658, 815
Kaplan H, 616, 632
Kaplan M, 615
Kaplan S, 626
Karsh J, 111, 626, 764, 1055, 1321

Kashiwado T, 666
 Kaslow R, 649, 659
 Kass E, 71
 Kassan SS, 209, 449, 616, 1382
 Katz A, 1039
 Kaufman R, 627
 Kay H, 591
 Kaye R, 659, 671
 Kean W, 495
 Kelly R, 658
 Kelley W, 639, 675
 Kelman J, 649
 Kelomaa-Sulonen K, 502
 Kemple K, 371
 Kennedy A, 651
 Kettys G, 400
 Keyser A, 627
 Keyser AJ, 983
 Khan MA, 597, 784, 628
 Khan MK, 628
 Killian P, 628
 Kim E, 845
 Kim HJ, 177
 Kimberly RP, 281, 305, 591, 629
 King DT, 203
 King KK, 593, 631, 633, 661, 954
 Kincaid S, 664
 Kingsland L, 675, 1334
 Kinsella T, 630
 Kirby J, 1146
 Kirsner A, 608, 630
 Kitridou R, 627
 Klineberg JR, 81, 371, 670, 703, 1029
 Klippel J, 626, 641, 647, 649, 764, 1055, 1321
 Kloforn RW, 1390
 Knotts LL, 236
 Kobayashi S, 123, 1064
 Koffler D, 458, 463, 674
 Kohler P, 777, 864, 1060
 Koike T, 123, 1064
 Korn J, 630
 Kornreich H, 593, 631, 633, 661, 954
 Kozin F, 177, 626, 637, 654, 886, 1082
 Kotzin B, 631
 Kraines R, 671
 Krane S, 604
 Krohel G, 832
 Kuhn RW, 1300
 Kumagai Y, 532
 Kunkel H, 633, 646, 1195
 Kurata N, 632
 Kurland L, 365
 Kushner I, 7, 321, 597, 628, 784
 Kwoh C, 632

L

Ladenbauer-Bellis I, 1117
 Lahita RG, 458, 463, 633, 674, 1195
 Lamera M, 633

Lane JM, 1093
 Laragh J, 603
 Latta L, 666
 Latulippe L, 95
 Lauter SA, 1421
 Lavallo C, 302, 308, 587
 Lawless O, 628, 635, 659
 Lawley T, 618
 Lee F, 631
 Lee V, 677
 Lehman T, 633, 954
 Leibold W, 371
 Lentle BC, 215
 LeRoy E, 630
 Levinson D, 634
 Levinson J, 601, 602
 Levy G, 826
 Lewis R, 649
 Ley J, 871
 Lian J, 634
 Liang GC, 77
 Lie JT, 820, 1088
 Lieu T, 635
 Lightsey AL, 1390
 Ligler F, 600
 Lindberg D, 675, 1334
 Lindsey S, 635, 659
 Lipinski E, 130
 Lippello L, 579, 635
 Lipsky P, 636, 651, 1352
 Lipton M, 1093
 Lison A, 667
 Llorente L, 586
 Lockshin MD, 281, 305, 591, 629, 637, 1382, 1424
 Loewenstein S, 617
 London WT, 1261, 1267
 Long S, 614
 Longcope C, 624
 Lopez-Ovejero J, 603
 Lorber A, 593, 636
 Lowe C, 703
 Ludivico CL, 19, 1024
 Luksick J, 130
 Lussier A, 939
 Luthra H, 433
 Lyons H, 614

M

MacCauley WL, 103, 204
 MacDermott R, 617
 MacFarlane JD, 164
 MacKenzie I, 806
 Maddison P, 796, 858
 Madura J, 711
 Maeda M, 1416
 Magana L, 302
 Malamud C, 637
 Malawista S, 471, 662, 728, 1135
 Malhotra CM, 837
 Maloney P, 1365
 Mandel N, 637
 Mandel G, 637
 Mandell B, 661

Mankin H, 579, 635
 Mann D, 610, 640
 Mannik M, 141, 642
 Mantzouraniz E, 595
 Marcus RM, 1396
 Markenson J, 637, 1132
 Mason J, 638
 Massarella JW, 1418
 Matsuta K, 655
 Maurer K, 170, 1024
 McCarty D, 389, 653, 654, 718, 886, 1082, 1122, 1394
 McClatchey W, 681
 McDevitt H, 606
 McDougal J, 629
 McDuffie F, 433, 617, 653, 740
 McDuffy S, 648, 988
 McGrath H Jr, 219
 McGrath PP, 845
 McIlwain H, 1146
 McIntosh RM, 864
 McKenna C, 365
 McLain DA, 306
 McLean R, 592
 McMillan R, 596, 1109
 McNeil R, 641
 Meagher P, 619
 Measel JW Jr, 310
 Mechel B, 202
 Medof M, 639
 Meenan R, 638, 675
 Mehta J, 659, 755
 Meisel AD, 605, 638
 Mejias E, 524, 639
 Melez KA, 1170
 Melhem R, 286
 Melish M, 621
 Mendes NF, 207
 Meo T, 590
 Merigan T, 606
 Merkatz IR, 202
 Messner R, 614, 657
 Meurer M, 433
 Meyer F, 642
 Michael SD, 1241
 Miguel J, 554
 Miller BL, 105
 Miller E, 602
 Miller G, 639
 Miller K, 596
 Miller J III, 502
 Miller SB, 1146
 Miller T, 463
 Miller W, 590
 Mills J, 590
 Millstein B, 637
 Minitier MF, 959
 Mirick G, 565
 Mirise R, 542
 Mitchell B, 639, 675
 Miyachi K, 87
 Molina J, 559, 672
 Mongan E, 600
 Moore R, 624
 Moore S, 642
 Moore T, 639
 Morgan A, 803
 Morgan B, 656

Morgan K, 598
 Morgan O, 684
 Morhaim D, 81
 Moroi Y, 640
 Morris A, 623
 Morris R, 777, 864
 Moskowitz RW, 52, 155, 202, 273, 637
 Moss R, 502
 Mouradian J, 281, 591
 Moutsopoulos H, 597, 618, 640, 641, 932
 Mowery C, 621
 Moy E, 616
 Moy WW, 251, 616
 Mueller RF, 77
 Mummaw J, 471
 Munck A, 1246
 Muniz O, 155
 Murphy ED, 1188
 Murray C, 610
 Myall R, 641
 Myawaki S, 632
 Myers AR, 19, 419, 1024
 Myers SL, 260, 641

N

Nagai Y, 1211
 Nakai H, 666
 Nardella FA, 141, 642, 662
 Naylor J, 642
 Nasonova V, 624
 Natarajan C, 638
 Natvig JB, 71
 Nelson AM, 820
 Nesbitt J, 659
 Nevitt M, 675
 Newcombe D, 673
 Newman JH, 1139
 Nigra T, 610
 Nilsson E, 978
 Nimni ME, 627, 983
 Nishikai M, 643
 Nomeir A, 518, 561
 Nuki G, 667
 Nusinow S, 643
 Nussenzweig V, 1399

O

O'Brien W, 591
 O'Connell D, 429
 O'Connor B, 644
 Offer R, 663
 Ofuji T, 632
 Ogawa H, 1405
 Ohno S, 1211
 Okudaira K, 666
 Olds-Arroyo L, 502
 Oliver M, 313
 Olnhausen RW, 1141
 Olufs R, 826
 Ongley R, 646
 Orozco AJJ, 1034
 Osborne C, 502

Osterland CK, 204, 590, 1421
Owen D Jr, 625

P

Pachman LM, 634, 826
Paget S, 643, 644
Pahle J, 71
Palmer DW, 718, 1122
Palmoski M, 508, 644, 746
Panayi G, 645
Papaionnou C, 653, 740
Parham N, 650
Parker M, 518
Parsons JR, 1102
Partridge N, 634
Pascual E, 547, 586
Pasero G, 804
Passero F, 419
Passo M, 645
Passwell J, 604
Pate D, 1039
Patarroyo M, 646
Patterson A, 646
Patterson M, 656
Paty JG Jr, 98
Paulus HE, 105, 384, 599, 604, 1018
Pavia CS, 1300
Pavlidis N, 641
Peebles C, 640, 667
Percy JS, 215, 599
Perez H, 646, 1326
Perlsh J, 609
Perlman D, 610
Perricone E, 508
Persellin R, 605
Petty R, 602
Philips V, 423
Phillips PE, 209, 643, 644
Pidoux I, 647
Piening U, 896
Pierce DA, 911
Pinals R, 396
Pisko E, 518, 647
Pita JC, 155
Pittik S, 1416
Plotz P, 647
Pollard K, 622
Poole A, 614, 647
Pope R, 605, 648, 677, 988
Postlethwaite A, 665
Powell MR, 809
Poznansky M, 599
Prete P, 792
Prince R, 608
Procknal JA, 826
Pruitt N, 647

Q

Quismorio F, 565, 627, 983

R

Racela L, 586
Radin E, 649, 665
Radioiu N, 1422

Ragsdale C, 602, 649
Ramos-Niembro F, 43, 935
Raveche ES, 1170, 1177
Reeve C, 663
Reeves JP, 1170
Reginato AJ, 170, 590, 928
Reichlin M, 643, 858
Reinecke RD, 832
Reiner A, 647
Reinertsen JL, 145, 649, 655, 770
Reinoso SR, 308
Revach M, 1417
Rhoades G, 328
Ribas-Mundo M, 554
Rich K, 524
Richmond J, 94
Rigby RJ, 94
Riley RL, 219
Riskin W, 666
Ritchie JC, 260
Roberts N, 599, 904
Robinson D, 650
Robinson H, 663
Rodnan GP, 130, 608
Rogoff JB, 309
Rohe KM, 1420
Rooks WH II, 1365
Roos D, 633
Ropes MW, 945
Rosano C, 650
Rosenak B, 376
Rosenberg D, 661
Rosenberg L, 647
Rosenberg S, 651
Rosenfeld B, 637
Rosenfeld JB, 1416
Rosenspire K, 651
Rosenstock D, 588
Rosenwasser L, 651
Rosman PM, 937
Rosner IA, 52
Rothberger H, 518, 652
Rothermich N, 423
Rothfield NF, 13, 592, 649, 652
Roths JB, 1188
Roubinian J, 1162, 1399
Rovira J, 590
Rowell N, 429
Roy R, 95
Rubin RL, 864
Rubinow A, 653
Rubinstein H, 426
Ruddy S, 13, 403, 471
Ruiz-Arguelles A, 59
Ruoslahti E, 627, 983
Rupp S, 277
Russell AS, 215
Russell I, 653
Rutstein J, 648
Ryan LM, 653, 654, 886
Ryan W, 547
Rynes R, 654, 832
Rytel K, 626

S

Saal S, 603
Sacerdote A, 937

Sacksteder M, 334
Sadakian JA, 1162
Sadeghian M, 547
Sadovnikoff N, 837
Sakane T, 655, 770
Sakurami T, 1405
Samuelson CO, 182, 290
Sapolsky A, 655
Sawada S, 655
Sauter S, 403
Scarborough D, 639
Schaefer J, 557
Schaller J, 641, 656, 669
Scheinberg MA, 207
Schenck JF, 1037
Schiafapachasse V, 928
Schiffman G, 1321
Schiller A, 649
Schlappner O, 663
Schlesinger M, 815
Schlossman S, 595
Schnapf D, 628
Schnitzer B, 669
Schocket AL, 1060
Schrohenloher R, 440, 484, 557
Schultz J, 590
Schumacher HR, 170, 547, 559, 590, 928, 1142
Schumacher R, 672
Schuna AA, 198
Schur P, 592, 656
Schwab JH, 25
Schwartz M, 728
Scott ME, 260
Seaman WE, 657, 1234
Searles R, 657
Sedgwick J, 657, 658
Seegmiller J, 605
Segura F, 554
Seibold J, 658
Selznick M, 658
Serdula M, 328
Sergeant JS, 97
Servello L, 650
Shadle CA, 1093, 1102
Shandling M, 599
Shapiro MS, 936
Sharp G, 618, 675, 1334
Sharrow S, 597
Shaw M, 598
Shear E, 602
Shear S, 542
Sheon R, 608, 630
Sherman R, 629, 1132
Sherman RL, 281, 591
Sheth K, 781
Shiokawa Y, 532
Shirai T, 123, 1064
Shott L, 1365
Shreffler D, 590
Shulman L, 659
Sibinga M, 614
Siitri PK, 1162, 1284, 1300
Silvoso G, 623
Simborg D, 673
Simchowitz L, 659, 661, 755
Simkin PA, 99, 608, 689
Simon BG, 932

Simon D, 659
Simon T, 636
Singer J, 662
Singhal S, 593
Singsen B, 593, 631, 633, 661, 954
Skinner M, 653, 677
Skosey J, 632, 643
Slavin S, 632
Sledge C, 664, 871
Sliwinski AJ, 200, 660
Sloan TB, 260
Smathers PA, 1170
Smiley J, 622, 642
Smith KA, 1246
Smith PW, 1141
Smith RC, 1211
Smith RD, 1419
Smukler N, 547
Snyder K, 635
Sokoloff L, 208
Solomon S, 430
Soloviev S, 624
Sonnenfeld G, 606
Sontheimer R, 660
Soriano E, 554
Sorin S, 273
Soter N, 656
Spencer C, 661
Speransky A, 624
Spielberg I, 427, 659, 661, 755
Spyker D, 674
Srinivasan R, 105
Stacey M, 617
Stack M, 662
Stahl NI, 1321
Stamm S, 656
Stapleton DD, 1211
Starkebaum G, 662
Stastny P, 612
Statius van Eps LW, 1414
Steere AC, 300, 471, 662
Stein H, 646, 663
Steinberg AD, 114, 145, 624, 641, 649, 655, 674, 770, 1170, 1177, 1321
Steinberg J, 664, 877
Steinman C, 629, 664, 1413
Sterba G, 605, 638, 815
Stern R, 911
Stevens M, 589, 594, 623, 665
Stites DP, 1300
Stobo J, 651
Stollar BD, 959
Strauss D, 648
Streeten D, 396
Strelkaukas A, 595
Striker G, 669
Strober S, 425, 631
Strosberg JM, 1037
Stross J, 787
Strottman M, 672
Stuart J, 347, 665, 1344
Su E, 622
Sullivan D, 602
Sullivan M, 672
Sundstrom WR, 198
Swaak AJG, 226, 1414

Swann D, 665
Sylvester RA, 809

T

Takasugi S, 675
Talak N, 655, 657, 809, 911, vi,
1162, 1399
Tan EM, 87, 609, 616, 617, 635,
640, 641, 667
Tanaka S, 1405
Tancredi RG, 1088
Tang L, 647
Tanimoto K, 666
Tapla L, 305
Taplitz MS, 66
Tappeiner G, 433
Taragan R, 936
Taurog JD, 1170
Taylor J, 684
Taylor RP, 219
Teller D, 642
Tello R, 102
Tenebaum J, 666
Termini RE, 999
Teufel A, 646
Thanki S, 654
Theofilopoulos A, 604
Thomas A, 667
Thomas M, 423
Thor L, 606, 1074
Thorne R, 792
Thuning C, 334
Tice A, 622
Tichy M, 101
Tingle A, 400
Tipton C, 667
Tjio JH, 1177
Tominaga Y, 1405
Torretti D, 668

Tourtellotte C, 614
Townes A, 347, 665, 1344
Trapani R, 668
Tsukamoto S, 664, 877
Turner R, 518, 559, 561, 647,
672

U

Ueo T, 1405
Ugai K, 353, 1352
Uribe-Uribe O, 1013
Utsinger P, 667, 668

V

van Boxel J, 668
van der Rest M, 614
Van Eps LWS, 226
Vayuvegula B, 565
Veherano A, 646
Vergalla J, 111
Vitetta E, 600
Volanakis J, 440, 484
Volz R, 669

W

Wachtel SS, 1200
Wahl R, 590
Walker S, 669, 1338
Wallace C, 656, 669
Wallace DJ, 81, 670, 703
Wallace EZ, 937
Waller ES, 1418
Wallis J, 637
Ward JR, 182, 670
Ward S, 642
Warren J, 334
Washburn L, 670

Washington GC, 845
Wasner C, 671
Waterman JR, 1006
Watts L, 561
Waycott S, 1139
Waytz P, 490
Webb S, 554
Webster R, 646
Wedgewood R, 669
Weinberger A, 559, 672, 1142
Weiner DJ, 1142
Weiner G, 426
Weiner M, 815
Weinlein L, 1170
Weinstein A, 672
Weisbart R, 1018
Weisman M, 922, 940
Weiss T, 639, 677
Weitzner R, 426
Wener M, 672
Wessinghage D, 1420
West E, 1365
West R, 641
Wheeler DA, 1308
Whiting-O'Keefe O, 673
White S, 426
Whitney SL, 260
Wigley F, 673
Wilgram G, 615
Wilkenfeld MJ, 200
Williams BW, 114, 145, 313
Williams CH Jr, 260
Williams G, 674
Williams JH, 290
Williams R Jr, 614
Wilson CH Jr, 1146
Wilson H, 458, 674
Wilson JD, 675, 1275
Wilson W, 684, 803
Winchester R, 646, 662

Winfield JB, 1, 458, 674
Winkelstein A, 594, 608, 1006
Winn D, 675, 1334
Witrak GA, 938
Witz IP, 1308
Woessner J Jr, 655
Wolfe B, 832
Wolfe J, 675, 1334
Wolinsky S, 614
Wong K, 599
Wood A, 871
Woods V, 597
Wooley P, 645
Woosley RL, 97
Wortmann R, 524, 675
Wright D, 626, 1055

Y

Yakatan GJ, 1418
Yelin E, 675
Yood R, 597, 677, 1361
Yoshiki T, 123, 1064
Yoshinoya S, 677
Yount W, 403
Yunus M, 596

Z

Zabriskie J, 646
Zapanta M, 711
Zein N, 7
Ziff M, 353, 636, 697, 999, 1352
Zimmerman T, 652
Zizic T, 624, 665
Zmijewski CM, 928
Zuckner J, 639, 677
Zulman J, 911
Zvaifler N, 605, 649

SUBJECT INDEX

Arthritis and Rheumatism, Volume 22, Numbers 1 through 12, 1979

Italic page numbers indicate Abstracts presented at 43rd Annual Meeting of The American Rheumatism Association, May 30 through June 1, 1979.

A

- Abdominal aortic aneurysm, in Forestier's disease, 800-801
- Abdominal pain in hereditary angioedema, 1295
- Aberrant sexual differentiation, H-Y antigen in, 1202
- Abnormal gonadal differentiation, 1208
- Abstracts, ARA, submitted/acceptance rate, 1042
- Acetylators, fast ionazid, 96
- Acromegaly, skin thickening in, 135-136
- Acrosclerosis, 130, 137
 - see also* CREST syndrome
- Actinomycin D, 1249
- Acute gouty arthritis, *see* Gouty arthritis
- Acute monocytic arthritis, 294-298
 - adenovirus and, 301
 - causes of, 298
 - vasculitis in, 297
 - viruses related to, 301
- Acute renal failure, aspirin and ibuprofen in, 281-284
 - see also* Kidney; Renal disease
- Acute rheumatic fever, HLA-B5 antigen and, 677
 - see also* Rheumatic fever
- ADCC, *see* Antibody-dependent cell-mediated cytotoxicity
- Addison's disease, musculoskeletal manifestations of, 558
- Adenoma, pulmonary, in New Zealand mice, 1338-1343
- Adipocytes, 1287
- Adipose tissue, extraglandular estrogen formation in, 1286
- Adjuvant activity, Type II collagen in, 601
- Adjuvant arthritis
 - antiinflammatory and bone protective effects of diphosphonates in, 340-346
 - connective tissue in, 1365-1374
 - hyperbaric oxygen in, 336-337
 - indomethacin in, 1372
 - as model for human arthritis, 1365
 - naproxen in, 1365-1374
 - prednisolone in, 1372
 - radiologic studies, 1366-1373
 - in rats, 532
- Adjuvant disease, human, *see* Human adjuvant disease
- Adjuvant model, inflammatory process in, 345
- Adrenocortical carcinoma, in SLE, 937-939
- Aerobacter aerogenes*, 1040
- AFP, *see* Alpha-fetoprotein
- Aggregation defect, *see* Platelet aggregation; Proteoglycan aggregation defect
- AHP, *see* Arthritis Health Professionals
- Albumin
 - urate binding to, 735-738
 - urate as inhibitor of, 735
- Albumin-bound steroid hormones, 1289
- 5 α -Reduced androgens, 1288
- 5 α -Reductase, 1280-1281, 1287
- Alpha-1-Antitrypsin phenotypes, in RA and SLE, 111-112
- Alpha-fetoprotein, during pregnancy, 1303
- Alpha-tocopherol, preservation of articular cartilage, 1093-1101
- American Association for the Study and Control of Rheumatic Disease, 1041-1042
- American Board of Internal Medicine, 187, 201
- American Rheumatism Association, 109, 187, 195, 201, 329, 429
 - abstracts of 43rd Annual Meeting, 586-678
 - abstracts, submitted/acceptance rate, 1042
 - history, 1394
 - income and expenses for 1978, 1395
 - membership, 1049
 - Presidential Address to, 1041-1054
 - relationship to Arthritis Foundation, 1394-1395
- American Rheumatism Association Medical Information System, 1029
- American Rheumatism Uniform Database, 1029-1033
- American rheumatologists, training of, 187-196, 201
- Amino acid composition, of connective tissue activating peptide, 262-264, 269
- Aminoglutethimide, 1288
- Aminoglycosides, in acute renal failure, 282-283
- Amitriptyline, 451, 456
- Amyloid, research in, 1053
- Amyloid protein A, *see* Serum amyloid protein A
- Amyloidosis
 - bone-seeking radionuclide uptake in, 677
 - chyloous pleural effusions in, 182-186
 - protein and erythrocyte sedimentation rates in, 653
 - serum amyloid in, 36-41
 - sicca syndrome and, 932-934
 - SLE and, 554-556
- ANA, *see* Autoantibodies to nuclear antigens; Antinuclear antibodies
- Androgen receptor
 - defects, 1281
 - mutation, 1282
 - in 5 α -reductase deficiency, 1280
 - in testicular feminization, 1281
 - tissue level of, 1289
- Androgen sensitivity in sex differences, factor in immune response, 1218-1233
- Androgen-dependent sexual differentiation, 1288
- Androgens, 1167, 1168, 1170, 1171, 1173, 1174, 1186, 1235, 1296
 - action, hereditary defects in, 1279-1282
 - antibodies to nucleic acid, 1166
 - erythropoiesis and granulopoiesis, 1221
 - and estrogen production, 1284-1285, 1288-1289
 - and estrogens in human fetal liver, 1287
 - immune response, 1220-1222, 1225, 1227-1228

Androgens (continued)

- immunoglobulin levels, 1224
- production, 1284
- in target cells, 1279
- Androstenedione, 1285-1287
- Anemia, chronic hemolytic, 803
- Angioedema, 1296
- Angiokeratomas, in Fabry disease, 782
- Angiotensin converting enzyme inhibitor, 603
- Animal models, *see* MLR/1 mice; New Zealand mice
- Ankylosing chondrocalcinosis, 928-932
- Ankylosing hyperostosis of the spine, 799-802
- Ankylosing spondylitis
 - age- and sex-specific incidence of, 367
 - atlantoaxial subluxation in, 273-275
 - and Cw1, Cw2 complement fractions in B27-positive and B27-negative patients, 373
 - deaths from, 368-369
 - decreased survival in, 628
 - diagnostic criteria for, 365
 - diseases related to, 369
 - epidemiology of in Rochester, Minn., 365-369
 - genetic heterogeneity in, 628
 - histocompatibility testing in, 365-366
 - HLA-B27 antigen and, 302, 366
 - HLA-D locus and, 94-95, 371-374
 - juvenile, 593
 - male vs. female incidence of, 368-369
 - MLC response level in, 374
 - monocyte leukotactic defect in, 597
 - multiple sclerosis and, 784-785
 - phagocytosis of immunoglobulin-containing inclusions in, 630
 - prevalence rates for, in Western Europe, 366
 - and RA in same family, 203-204
 - sacroiliitis and, 303-304, 939
 - survivorship curves for, 367-368
 - tarsal tunnel syndrome in, 77-79
 - T lymphocytes in, 978-981
- Antibodies, 1303-1304
 - assay for lymphocytotoxic, in SLE, 1064-1073
 - cold-reactive lymphocytotoxic in SLE, 1060-1063
 - effects of cyproterone on, 1166
 - effects of danazol on, 1166
 - induced, 1178-1182
 - to nuclear ribonucleoprotein, 91-92
 - to T cells, 1064-1065, 1070-1071
- Antibody-dependent cell-mediated cytotoxicity
 - in RA, 490-493
 - T cells in, 981
- Antibody deposition, in SLE, 858-862
- Antibody production, 1185
 - effect of prepubertal castration on, 1167, 1179
- Antibody rebound phenomenon, 1149
- Antibody response to bovine serum albumin, 1225
- Antibody specificity, in IgG and IgM autoimmune complexes, 589
- Anti-brain antibody
 - CNS dysfunction and, 458-462
 - epilepsy and, 462
 - in SLE, 674
- Anti-C1 inhibitor, 1296
- Anti-CNS antibodies, in SLE, 1382
- Anticoagulant against Factor XIa in SLE, 1135-1138

- Anticonglutin, 617
- Anti-cytoplasmic ribosomal antibodies
 - precipitating antibodies and, 466
 - radioimmunoassay detection of, 469
 - specificity of, 465-466
- Anti-Daudi cytotoxicity, 1213-1214
- AntiDNA antibodies
 - in cyclophosphamide therapy, 1340
 - generation of, 593
 - in New Zealand mice, 413-415, 603
 - production of in murine lupus, 655
 - suppression by cyclophosphamide, 1338
 - in SLE, 219-224
- Anti-dsDNA
 - complement-fixing activity of, 565-570
 - in SLE, 226-234
- Antifetal immune reactivity, 1308
- Anti-Fc antiserum, specificity of, 990-991
- Antigen-antibody systems, in Sjögren's syndrome and SLE, 796-798
- Antigen-responsive lymphocytes, 1253
- Antigens, precipitating antibodies to, 87-92
- Antiglobulins, platelet aggregation and, 896-902
- Anti-H-2 antibodies, 1303-1304
- Anti-HBs antibody, 1261, 1262, 1264, 1267
- Antiheparin factor, 261
- Antihypertensives, in management of scleroderma, 1132-1134
- Antiimmunoglobulin antibody producing cells, IgG and, 647
- Antiinflammatory drugs
 - glucocorticoids, 1246-1247
 - liposome encapsulation of, 599
 - nonsteroidal, 376, 383, 671
 - in superoxide generation by neutrophils, 659
- Antiinflammatory effects, of diphosphates in adjuvant arthritis, 340-346
- Antilymphocyte antibodies
 - cross-reactivity of, 657
 - in SLE, 666
- Anti-native DNA, *Crithidia luciliae* and, 321-326
- Anti-neuroblastoma antibodies, in SLE, 460
- Antineuronal antibody
 - absorption of, 317
 - cross-reaction of with erythrocytes and lymphocytes in SLE, 313-319
 - neuropsychiatric involvement and, 316-317
 - serial measurements of in SLE patients, 319
- Antinuclear antibodies, 1191
 - in childhood SLE, 633, 955-958
 - cross-reactivity of, 657
 - in cyclophosphamide therapy, 1340
 - in hypernephroma, 1396-1398
 - in JRA, 502
 - in rheumatoid sera, 667
 - in scleroderma, 640
 - in SLE, 633, 948, 955-958
 - in suppressor cell function, 586
- Antinuclear factor, in pregnancy, 201-202
- Antiribosomal antibodies
 - in SLE sera, 463-469
 - specificity and clinical correlation of, 463
- Anti-ssDNA antibodies, 1182, 1185

- Anti-T cell antibodies (NTA), 1064-1065, 1070-1071, 1177, 1182-1185
 effect of testosterone on production of, 1184, 1185
 immunofluorescence studies of in SLE, 114-121
 in JRA, 595
 in New Zealand mice, 123-128
- Antithymocyte, serum, 1229
- Aortic aneurysms
 in Forestier's disease, 800-801
 vertebral erosion and, 801
- Aortic arch syndrome, 684-688, *see also* Takayasu's arteritis
- Aplastic anemia, 1270
 antibody-mediated, 659
 bone marrow transplantation in, 1267, 1271
- Articular cartilage, macronuclear organization of, 644
- ARA, *see* American Rheumatism Association
- Arachnodactyly, congenital contractural, 542-545
- ARAMIS (American Rheumatism Association Medical Information System), 1029
- Aromatase enzyme, 1286, 1287
- Art and rheumatology, 1041-1054
- Arteritis, giant cell, *see* Giant cell arteritis
- Arteritis, Takayasu's, *see* Takayasu's arteritis
- Arthritis
 acute monocytic, 294-298
 adjuvant-injected rat model, 1365
 child resistant cap syndrome, 1422
 colchicine in, 661
 collagen-induced, 347-352, 601, 1344-1351
 after frostbite injury in children, 1082-1087
 health status measurements in, 638
 inflammatory bowel disease and, 645
 after jejunioileal bypass, 711-717
 due to *Listeria monocytogenes*, 1139-1140
 literary history of, 1043
 due to *Mycoplasma pneumoniae*, 1375
 mycoplasma-induced, 670-671
 mycosis fungoides and, 424-425
 nonsteroidal antiinflammatory drugs in, 376
 plasma cyclic nucleotide levels in, 654
 psoriatic, *see* Psoriatic arthritis
 in rats, *see* Rat arthritis
 research support for, 1049-1052
 rubella, *see* Rubella arthritis
 rheumatoid, *see* Rheumatoid arthritis
 Salmonella reactive, 663
 on stamp collections, 538-541
 streptococcal-induced, 25-35
 traumatic, synovial fluid analysis in, 1362-1363
 Type II collagen in, 598
 urate-crystal induced, 661
 viral, 301
- Arthritis and Allied Conditions, book review, 1423
- Arthritis centers, multipurpose, 1051
- Arthritis Crafts Shop, 1047-1049
- Arthritis-dermatitis syndrome
 immune complexes in, 19-23
 postintestinal bypass in, 663-664
- Arthritis Foundation, 787
 budget of, 1052
- Arthritis Foundation (continued)
 relationship to the ARA, 1394-1395
 research support by, 1049-1052
- Arthritis Health Professionals (AHP), membership of, 1049
- Arthritis programs, state, 1050
- Arthritis and Rheumatism, 1052-1053
 guidelines for special issues, 1063
 income and expenses in 1978, 1395
- Arthropathy
 cell-mediated immune mechanisms in, 68
 mutilans-like, in MCTD, 1013-1017
- Arthroplasty
 in classic hemophilia, 613
 of hip, 602
 total wrist, 669
- Articular cartilage, *see* Cartilage, articular
- Articular surfaces, PMN attachment to, 355-356
- Aspirin, *see also* Salicylates
 in acute renal failure, 281-284
 bleeding and, 376-378, 1034
 and collagenase synthesis, 1109, 1114
 compared with fenoprofen as to gastrointestinal effects, 376-383
 enteric-coated, 1034-1036
 fecal blood loss and, 376-378
 gastrointestinal effects of, 376-383, 623, 1034
 in JRA, 826-830
 in Lyme arthritis, 474
 as nonsteroidal antiinflammatory agent, 383
 and prostaglandins, 1109, 1114
 regular and enteric-coated, 1034-1036
- Associative recognition, 1155, 1156
- Ataxia telangiectasia, 1241
- Atlantoaxial subluxation, ankylosing spondylitis and, 273-275
- Auranofin (oral gold) therapy, 615, *see also* Chrysotherapy
 vs. gold sodium thiomalate therapy, 636
 reversible proteinuria and, 1417-1418
- Aurosomes, 1359
- Australia antigen, 1261, 1262
- Autoantibodies, 1185
 inheritance of, 1177
 natural thymocytotoxic, of New Zealand mice, 1064-1073
 to nuclear antigens, 87-92
 precipitating, 707
 and sex hormones in SLE, 1164, 1165, 1195
- Autoantibody production, major histocompatibility genes in, 616
- Autocoid, mitogenic effects of, 267
- Autoimmune disease of mice, 1193
 and natural killer cells, 1234
 serum interactions in MRL/l mice 1074-1081
- Autoimmune syndrome, 1191
- Autoimmunity, 1185, 1239
 and age of sex hormone manipulation, 1173-1174
 in New Zealand mice, 412-417
 role in chronic mycoplasma arthritis, 1378
 role of sex hormones in, 1170-1176
 and sex factors, 1161-1198
 sex hormone modulation of, in New Zealand mice, 1162-1169
 strontium in reduction of, 657
 and Y chromosomes, 1188-1194
- Autologous mixed lymphocyte reactions, 770-775

Autoreactivity, in MRL/1 mice, 1074-1081
 Autosomal and X-linked genetic control of antibodies, effect of sex hormones on, 1177-1187
 Autosomal recessive locus, 1206
 Avlosulfon, in relapsing polychondritis, 204
 Azathioprene
 adrenocortical carcinoma and, 937-939
 oncogenicity in New Zealand mice, 1342
 in SLE nephritis, 624, 868-869

B

β -1H globulin
 in immune renal disease, 403-410
 in SLE, 13-17
 β_2 m-HLA antigen, 1211, 1214
 anchorage sites for H-Y antigen, 1207-1208
 β_2 m-MHC antigen dimer anchorage sites, 1215
 B cells, 1154, 1159
 and pregnancy, 1219
 regulation by mononuclear phagocytes, 1352
 in SLE, 3-4
 see also Lymphocytes
 B:T cell ratio in pregnancy, 1219
 Baboon endogenous virus, 1308
Bacillus proteus, 1040
 Bacterial infection, in bursa, 1361-1364
Bacteroides fragilis, in Forestier's disease, 799-801
 Barbiturates
 in CNS lupus, 451
 CSF-CGMP levels and, 456
 Basement membrane collagen, in rat arthritis, 351-352
 see also Collagen
 Behavioral differences, HBV carriers, 1264
 Behçet's syndrome, palate perforation in, 308
 Benign hypermobile joint syndrome, 625
 Benzyl alcohol, synovial permeability to, 694
 BEV, see Baboon endogenous virus
 Birth control pills and hereditary angioedema, 1296
 Black patients
 Felty's syndrome in, 999-1003
 sickle hemoglobin and SLE in, 611
 Black women, giant cell arteritis in, 202-203
 Bleeding, gastrointestinal, see Gastrointestinal bleeding
 Bleomycin-induced scleroderma, 608-609
 Blood platelets, see Platelets
 Blood sera
 gammaglobulin-minus-IgG values for, 142-143
 lymphocytotoxicity of, 317
 Bone, Paget's disease of, see Paget's disease of bone
 Bone marrow, effects on natural killer cells, 1238-1239
 Bone marrow transplantation, 1269-1270
 for aplastic anemia, 1267
 genetic resistance to, 1238
 progressive systemic sclerosis-like syndrome following, 904-910
 Bone-seeking radiopharmaceuticals, 837
 Bovine liver superoxide dismutase, 599
 Bovine serum albumin articular cartilage, 362
 Brain reactivity, psychosis and, 317
Brucella abortus arthritis, 806
 Burkitt's lymphoma, 915

Bursa, etiology of, 1361
 Bursa, superficial, reaction to disease, 1361-1364
 Bursa cells, effect of androgen on, 1222, 1229
 Bursitis
 gouty, 597, 1361-1364
 rheumatoid, 310
 septic, 622 1361-1364
 traumatic, 597, 1361-1364
 trochanteric, 940-941
 BXS mouse strain, 1189-1191
 autoimmunity in, 1194
 Y chromosome, 1193

C

C1 esterase, 1295, 1296
 C1 esterase inhibitor, 1297, 1298
 C3, see Complement C3
 Calcium pyrophosphate dihydrate crystals (CPPD)
 cartilage metabolism and, 726
 chemotactic factor and, 427
 clearance of, 1122-1131
 clearance of in vivo, 718-727
 in gout and pseudogout, 428
 monosodium urate monohydrate and, 575
 preparation and labeling of, 721
 purity of, 721
 pyrophosphate values in, 880-894
 in synovial fluid, 390-394
 synthetic, 718, 725
 Calf thymus extract, as antigen source, 797
Candida albicans, 71, 73
 Candida antigens, 741-743
 Canine articular cartilage, salicylate effect on proteoglycan metabolism in, 746-754
 Canine knee, immobilization of, 508-517
 Canine knee cartilage, proteoglycan aggregation defect in, 508-517
 Canine systemic lupus erythematosus, households exposed to, 649-650
 Captopril, in malignant hypertension in scleroderma renal vascular crisis, 603
 γ -Carboxyglutamate excretion, 634
 Carcinoma, in New Zealand mice, 1338-1343
 Cardiopathy, in polymyositis, 1088-1092
 Cardiac involvement, in RA, 561-564
 Carpal tunnel syndrome, cost containment in, 308, 1415
 Cartilage
 articular
 chloroquine and E-prostaglandins, 1117-1121
 preservation and storage of, 1093-1101
 viscoelastic measurement of, 1103
 loss in adjuvant arthritis, 1371
 polymorphonuclear leukocytes-immune complexes interaction in, 1416
 transplantation of, 1093
 Cartilage breakdown, tissue culture model of, 877-884
 Cartilage proteoglycan alterations, in rabbit osteoarthritis, 155-162
 Cartilaginous matrix, enzyme depletion and, 67
 Catechol estrogens, 1198
 Catullus, 1043
 CBG, see Corticosteroid-binding globulin

- CCA, *see* Congenital contractural arachnodactyly
- Celiac disease, HLA-B8 antigen in, 373
- Celite eluate test, 1136
- Cell markers, individual, 1159
- Cell surface component, male-specific, 1200
- Cell surface programming, 1154
- Cellular communication and differentiation, 1153-1160
- Cellular cytotoxicity, PHA-induced, 59-63
- Centers, multipurpose arthritis, 1051
- Central nervous system dysfunction, IgG anti-brain antibodies and, 458-462
- Central nervous system lupus erythematosus, 449-456
classification of, 1382-1385
computed axial tomography and, 628-629
DNA antibodies, association with, 1334-1337
- Centrifugation, continuous flow cell, 1055-1059
see also Lymphapheresis
- Cerebrospinal fluid
antineuronal antibodies in, 674
C-GMP changes in, 453
C-GMP concentrations of in SLE, 450-451
immune complexes in, 658
- CFU, *see* Pluripotential stem cells
- C-GMP, *see* Cyclic guanosine 3',5'-monophosphate
- Chemotactic activity
and infection in SLE, 1326-1333
generation in sera, 1327
- Chemotactic factor inactivator (CFI), in SLE, 1326-1333
- Child resistant cap syndrome, 1422
- Childhood dermatomyositis
cutaneous ulceration in, 602
muscle histopathology as indicator of, 601
- Childhood, polyarteritis nodosa in, 820-824
- Childhood SLE, *see also* Systemic lupus erythematosus
renal history in, 669
serum complement abnormalities in, 954-958
- Children, arthritis after frostbite in, 1082-1087
- Chlorambucil, in SLE nephritis, 624-625
- Chloroquine, and prostaglandins in articular cartilage, 1117-1121
- Chlorpromazine, in CNS lupus, 451, 456
- Cholesterol conversion to pregnenolone, 1277
- Choline magnesium trisalicylate, 384-387
- Chondrocalcinosis, HLA antigens in, 928-932
- Chondrocyte glycosaminoglycan synthesis, suppression of, 621
- Chondroma, in New Zealand mice, 1340
- Chorionic gonadotrophins, 1303
- Chromosomal characteristics of variant Daudi cells, 1212
- Chromosomal sex, 1275
- Chronic active hepatitis in males and females, 1262
- Chronic HBV carriers, 1260-1264, 1267-1270
- Chronic liver disease, sex ratios in, 1258
- Chronic polyarthritis, X-linked hypergammaglobulinemia and, 71-75
see also Polyarthritis
- Chronic renal disease and hemodialysis, 1263-1264
- Chrysotherapy, *see also* Auranofin; Gold; Gold sodium thiomalate; Myochrysin
efficacy of, 495-496
followup study of, 423
gold excretion and retention in, 615
half-life of gold sodium thiomalate, 1418-1419
immune system and, 309-310
- Chrysotherapy (continued)
long-term, 495-501
vs. D-penicillamine treatment, 663
proteinuria and, 498, 1417-1418
in RA, 105-110
rash and mouth ulcers in, 498
side effects in, 423
toxicity in, 108-109, 497-500
- Chylous (chyliform) effusions, in RA, 182-186
- CIC, *see* Circulating immune complexes
- Circular bacteriophage DNA, 233
- Circulating cytotoxic autoantibodies, in Felty's syndrome, 668
- Circulating immune complexes
immunoassays for, 433-438
in MCTD, 484-488
in progressive systemic sclerosis, 518-522
in SLE nephritis, 635, 703
- Circulatory-metabolic imbalance, in RA, 689, 695
- CL, *see* *Crithidia luciliae*
- Cl₂MDP, *see* Disodium chloromethane diphosphonate
- Clonal selection theory, 1252, 1253
- Clonidine, in management of scleroderma, 1133
- Clostridia* discitis, 1039-1040
- Clostridia perfringens*, 1039-1040
- Clotting system, intrinsic, 1137
- CMT, *see* Choline magnesium trisalicylate
- CNS SLE, *see* Central nervous system lupus erythematosus
- Colchicine
in acute urate crystal-induced arthritis, 661
in gout, 103
in pseudogout, 427
- Cold-reactive lymphocytotoxic antibodies (LCA), in SLE and related diseases, 1060-1063
- Collagen, *see also* Hydroxyproline
basement membrane, 351-352
bovine vitreous, 347-352
cell-mediated immunity to, 665
murine T cell response to, 651
noncartilaginous source of, 350
and skin thickness in PSS and scleroderma, 130-140
type II
induction of arthritis, 1344-1351
preparation of, 1345
type III, 609
vitreous vs. cartilage-derived, 347-352
- Collagen accumulation, in scleroderma, 627
- Collagen gelation
inhibition of by superoxide radical action, 251-258
xanthine oxidase and, 254-256
- Collagen-induced arthritis
histopathology, 1348
Freund's adjuvant and, 349-350
in rats, 347-352, 598, 1344-1351
relationship to RA, 1350
- Collagenase and phorbol myristate acetate, 1109-1116
- Collagenase, production of, 1109-1116
- Collagenous tissues, of joints, *see* Joint collagenous tissues
- Communication and differentiation, cellular, 1153-1160
- Competition and H-Y antigen, 1208
- Complement, deficiency of, and cold-reactive lymphocytotoxic antibodies, 1060-1063

- Complement C1q, in SLE, 15
- Complement C1q binding assay, 433-434, 437-438, 440-447
in Felty's sign, 697-701
- Complement C2 deficiency, in lupus-like disease, 590
- Complement C3
abnormalities of in childhood SLE, 954-958
activation
calcium and, 576
inhibition of, 576
by monosodium urate monohydrate, 571-577, 620
in dermal-epidermal junction of SLE patients, 13-17
in immune renal disease globulin studies, 403-410
in immunofluorescence, 565
molecular weight of, 247
split products in, 502-507
- Complement C4
in adult SLE, 15
in childhood SLE, 955-958
- Complement C5, specific inhibition of, 646
- Complement abnormalities, in SLE, 15, 955-958, 1009-1010
- Complement activation, *see also* Complement C3, activation
crystal-induced, 620
by monosodium urate crystals, 612
by urate crystals, 653
- Complement-complement depletion, in mixed cryoglobulinemia, 1006-1011
- Complement fixation
in myositis, 210-211
by native DNA antibodies, 964-966
- Complement-fixing antibodies, to ssDNA, 565-570
- Complement level, in SLE, 231-232
- Complement-related hereditary angioedema, sex hormone effects on, 1295-1299
- Computed axial tomography, of central nervous system lupus, 628-629
- Con A-activated suppressor T cells, in SLE patients, 125-126
- Congenital contractural arachnodactyly, 542-545
- Congenital osteopetrosis, 1238-1239
- Connective tissue, effects of naproxen on, 1365-1374
- Connective tissue activating peptide-III, 260-271
amino acid composition of, 264, 269
antibodies to, 262
drug regulation of DNA synthesis by, 268
factors related to action of, 265-266
properties of, 263
"specific activity" of, 265
- Connective tissue activation, 260-271
defined, 260
- Connective tissue cell DNA synthesis, 266
- Connective tissue diseases, *see also* Mixed connective tissue disease
cytotoxic agents in, 938
sex factors in, 658-659
- Conservation of H-Y antigen, 1201
- Continuous flow cell separator, 1055
- Copper sulfate, helper T cell inhibition by, 636
- Corticosteroid-binding globulin (CBC), 1289
- Corticosteroid therapy, SLE survival and, 945-951
- Corticosteroids
cost of injections, 1415
fatty lesions and, 199-200
masking infection in SLE, 1421
and polymyositis, 1091
- Cortisol, 1248, 1249
- Cosmetic surgery, scleroderma following, 532-536
- Counterimmunoelectrophoresis, in detection of *Propionibacterium acnes*, 969-976
- CPPD crystals, *see* Calcium pyrophosphate dihydrate crystals
- Crataegus crus-galli*, 1037
- Creatine phosphokinase
myositis and, 210
in polymyalgia rheumatica, 277
- C-reactive protein detection, rheumatoid factor and, 605
- C-reactive protein, relationship to infection in SLE, 1421
- C-reactive protein response, in SLE, 7-11
- CREST syndrome, 130, 137-139, 595
- Crithidia lucillae*, 8, 205, 565, 955
in anti-native DNA detection, 321-326
- Cross-reactivity hypothesis, 1201, 1269-1272
- CRP, *see* C-reactive protein
- Cryoglobulin IgM, Lyme arthritis and, 471-482
- Cryoglobulinemia, mixed, in "healthy" family, 1006-1011
- Cryoglobulins
in procainamide-induced lupus syndrome, 305-306
in progressive systemic sclerosis, 522
in Sjögren's syndrome, 522
- Crystals, calcium pyrophosphate dihydrate, *see* Calcium pyrophosphate dihydrate crystals
- CTAP-III, *see* Connective tissue activating peptide-III
- Cushing's syndrome, 199
- Cutaneous lupus erythematosus, subacute, 612
- Cyclic GMP, in cerebrospinal fluid of SLE patients, 449
see also Cyclic guanosine 3',5'-monophosphate
- Cyclic nucleotides
in arthritic patients, 654
levamisole in alteration of, 240-241
- Cycloheximide, 1249
in protein synthesis, 760
- Cyclophosphamide
bladder complications in use of, 647
fatty lesions of humeri and, 199-200
neoplasms produced by, 1338-1343
oncogenesis and, 669, 1338-1343
and plasmapheresis, 1149
ribavirin and, 149
in SLE nephritis, 624
- Cyproterone acetate, 1166-1167
- Cytoplasmic and nuclear complexes, 1248
- Cytoplasmic antigen, in SLE nephritis, 858-862
- Cytoplasmic ribosomes, antibodies reactive with, 466-469
- Cytosine arabinoside and DNA synthesis, 1112, 1114
- Cytotoxic drugs and plasmapheresis, 1149
- Cytotoxic T cells, 1252
- Cytotoxic therapy, malignant disease and, 608

D

- Dactinomycin, in murine lupus nephritis, 151
- Dactylitis, subacute sarcoid, 1403-1404
- Danazol, 1162, 1167-1170, 1174
in hereditary angioedema, 1297-1298
in New Zealand mice, 1399-1402
- Dane particle, 1260

Daudi cells, 1207, 1208, 1211
 Deaminase inhibition, cyclic nucleotide levels in, 638
 Degenerative joint disease
 model of, 1107-1108
 RA and, 243-249
 Degradation of cartilage, and prostaglandins, 1119-1120
 DEJ, *see* Dermal-epidermal junction
 Delayed hypersensitivity, levamisole and, 239
 Deoxyadenosine toxicity, biochemical basis of, 676
 2-Deoxy-D-glucose, superoxide inhibition by, 759-760
 Deoxyguanosine triphosphate concentrates, 525
 Deoxyinosine, 529
 Deoxyribonucleoprotein, antibodies to, 469
 Deoxyribonucleoside toxicity, in T lymphoblasts, 675
 Deoxyribonucleoside triphosphate pools, 639
 Dermal-epidermal junction, C3 in, 13-17
 Dermatomyositis
 juvenile, 661
 precipitating antibody systems in, 643
 Toxoplasma gondii antibodies in, 209-214
 Dermatopolymyositis, MCTD and, 51
 Dexamethasone, 1248, 1251-1254
 Dextroamphetamine, in idiopathic edema, 399
 DHEAS in pregnancy, 1286
 DHT, *see* Dihydrotestosterone
 Dialysis and HBV infection in hemodialysis clinics, 1268
 Diazepam, 451
 in CFS C-GMP studies, 456
 Dibutyl-cyclic AMP, in proteoglycan synthesis, 662
 Dichloromethane diphosphonic acid, 340-346
 Differentiation of immune response, 1217-1256
 Diffuse idiopathic skeletal hyperostosis, 799-802, *see also* Forestier's disease
 Digoxin, in management of scleroderma, 1133
 Dihydrotestosterone, 1162, 1168, 1174, 1275, 1279-1281, 1286-12
 Dimethylpolysiloxane, 535
Dipetalonema, 1142-1145
 Diphosphonates, antiinflammatory and bone protective effects of, in adjuvant arthritis, 340-346
Dirofilaria immitis, 1142-1145
 Discitis, *Clostridia* as cause of, 1039-1040
 Discoid lupus erythematosus
 cold-reactive lymphocytotoxic antibodies in, 1060-1063
 properdin levels in, 592
 Disease
 CPPD crystal deposition in, 1122, 1127
 associated with HBsAg, 1262-1268
 Disease activity, hematologic markers of, 451-452
 DISH, *see* Diffuse idiopathic skeletal hyperostosis
 Disks, imaginal, 1158
 Disodium dichloromethane diphosphonate, antiinflammatory effects of in adjuvant arthritis, 340-346
 Disodium ethane-1-hydroxy-1,1-diphosphonate, 340-346
 Disseminated gonococcal arthritis-dermatitis syndrome, inner complexes of, 19-23
 Dissociation reaggregation, 1155
 DJD, *see* Degenerative joint disease
 DMSO and preservation of articular cartilage, 1093, 1098
 DNA, *see also* Anti-DNA antibodies; Anti-dsDNA; Anti-ssDNA
 circulating antibodies to, 238
 Crithidia luciliae and, 321-326

DNA (*continued*)
 double-stranded, *see* Double-stranded DNA
 single-stranded, 222-223
 tritiated thymidine incorporation into, 262
 DNA antibodies
 complement-fixing, 565-570
 in SLE, 1334-1337
 DNA/anti-DNA immune complexes, in vitro phagocytosis and degradation of, 633
 DNA-RNA synthesis activity, alkylation and, 584
 DNA synthesis
 autocoid and hormone effects on, in connective tissue cell cultures, 267
 drug regulation of, 268
 human granulocyte factor in, 641-642
 by human osteoarthritic cartilage, 637
 serum proteins and, 266
³H-DNA, in anti-DNA antibody studies, 220
 Double-stranded DNA, 220-224
 antibodies to in SLE sera, 565-570, 1009
 measurement in SLE, 1413-1415
 D-penicillamine, *see* Penicillamine
 Drug acetylation phenotype, 777-779
 Drug therapy in patients with hereditary angioedema, 1297-1298
 Drugs
 antihypertensive in management of scleroderma, 1133
 for rheumatoid vasculitis, 1148-1149
 "Dry eye" patients, serologic study of, 609
 Duplication, tandem, 1157
 Dwarfism, in Kniest syndrome, 286-289
 Dysgenetic "streak" gonads, 1206

E

EBV, *see* Epstein-Barr virus
 ECM, *see* Erythema chronicum migrans
 Edema
 causes of, 396
 idiopathic, in nonarticular rheumatism, 396-399
 "Effective synovial blood flow," 693
 EHDP, *see* Disodium ethane-1-hydroxy-1,1-diphosphate
 Elastofibroma
 incidence of, 795
 in periscapular pain, 792-795
 Elderly black women, giant cell arteritis in, 202-203
 Electroimmunoassay, of complement C3 in synovial fluid, 244-249
 Electromyography, in polymyalgia rheumatica, 277-280
 Electron beam therapy, in *Mycosis fungoides* arthritis, 424-425
 Electrophoresis profile of variant Daudi cells, 1214, 1215
 Elipten, *see* Aminoglutethimide
 Embryo, phenotypic differentiation of, 1277-1279
 EMG, *see* Electromyography
 Endocrine and immune system interactions, 1292
 Endocrine function in fetal gonads, 1275-1278
 Endocrine thymus, role in female reproduction, 1241-1245
 Enteric coated aspirin, 1034-1036
 Enzyme profile of steroid hormone biosynthesis, 1277
 Eosinophilic fasciitis, skin thickening in, 135-136
 E-prostaglandins, *see* Prostaglandins
 Epsilon amino caproic acid, 1296
 Epstein-Barr virus, 210

Epstein-Barr virus (continued)

- abnormal regulation of, 605
- immunoblastic lymphadenopathy and, 915
- in RA, 587
- in SLE, 845-855
- Epstein-Barr virus antigen, in RA, 588
- ER, *see* Estrogen receptor
- Erythema chronicum migrans, Lyme arthritis and, 471, 476
- Erythrocyte autoantibodies, 1190-1191
- Erythrocyte enzymes, deficiency, 526-528
- Erythrocyte inhibition assay for lymphocytotoxic antibodies in SLE, 1064-1073
- Erythrocyte sedimentation rate, serum amyloid A protein and, 40
- Erythrocytes, antineuronal antibody cross-reaction with, in SLE, 313-319
- Erythropoiesis and granulopoiesis, effect of androgens on, 1221
- Escherichia coli*, 1040
- Estradiol, 1173-1175, 1234-1236, 1243, 1275-1276
 - in animal osteoarthritis, 55-56
 - in follicular phase, 1285
 - in menstrual cycle, 1290
 - in obese postmenopausal women, 1290
 - in SLE, 1195, 1198
- Estradiol-binding protein, 1290, 1292
- Estradiol conversion in fetal ovary, 1277
- Estradiol in SLE, 1197-1198
- Estrogen, 1167, 1170, 1234-1235, 1243
 - and androgen production in women, 1284-1285
 - effect on immune response, 1219-1220
 - effect on natural killer cells, 1234-1240
 - effect on thymus, 1238
 - inhibitors, 1175
 - metabolism in SLE, 633, 1195-1198
 - production, 1195, 1284, 1286-1288
 - receptor, 1291
- Estrogen-dependent breast tumors, target tissue in, 1291
- Estrone
 - conversion of androstenedione to, 1288
 - and hepatic disease, 1287
 - in SLE, 1195
- Ethane-1-hydroxyl-1,1-diphosphonate, 340-346
- (¹⁴C) Ethane-1-hydroxyl-1, 1-diphosphonate, 389-394
 - air exposure or freezing effects in, 392-393
- Exocytosis, human peripheral blood neutrophils and, 632
- Exogenous estrogens in postmenopausal women, 1287-1288
- Extractable nuclear antigen, 557, 1013-1017
 - antibodies to, 1016
- Extraglandular estrogen formation in adipose tissue, 1286
- Extraovarian estrogen production, 1286-1288

F

- Fabry disease, arthropathy of, 781-783
- FACS, *see* Fluorescence activated cell sorter
- Factor XIa, anticoagulant against SLE, 1135-1138
- Factor XII deficiency, in SLE, 419-421
- Familial rheumatoid arthritis, 592
- fANA, *see* Fluorescent antinuclear antibody
- Farr DNA binding assays, in SLE, 228-229, 232

- Fasciitis, diffuse eosinophilic, 659
- Fc receptors, 1246, 1254, 1304
 - and glucocorticoids, 1253-1254
- Fecal blood loss
 - aspirin and, 376-378
 - gastroscopy scores and, 381
- Feline leukemia virus (FeLV), 1308
- Fellowships, arthritis, 1049-1052
- Felty's syndrome
 - Clq binding of immune complexes in, 697-701
 - causal factors in, 1003
 - circulating cytotoxic abnormalities in, 668
 - glomerulonephritis and, 1021
 - humoral and cellular immune aspects of, 662
 - in RA, 81, 85
 - rarity of in blacks, 999-1003
- FeLV, *see* Feline leukemia virus
- Female hormones, effect on immune response, 1219, 1222
- Female reproduction, role of endocrine thymus in, 1241-1245
- Female-specific histocompatibility antigen, 1201
- Femur, histology of, 1237
- Fenoprofen
 - blood loss and, 376-388
 - double-blind study of, 425-426
- Fertile XX females, wood lemmings, 1203-1204
- Fetal gonads, endocrine function in, 1275-1278
- Fetal ovary supernatant, effect on H-Y antigen binding, 1208
- Fetal pituitary hormones in steroid hormone synthesis, 1277
- Fetal testis hormones, 1279
- Fetomaternal immune relationship, 1308
- Fiberoptic gastroduodenoscopy, 376
- Fibroblast growth factor, 267
- Fibroblast prostaglandin synthesis, 630-631
- Fibroblasts, synovial, and collagenase production, 1109-1116
- Fibronectin
 - defined, 983
 - in progressive systemic sclerosis, 983-986
 - tissue distribution of, 983-984
- Fluorescence-activated cell sorter, in SLE studies, 114-121
- Fluorescence of nuclei, in pregnant women, 202
- Fluorescent antinuclear antibodies, in progressive systemic sclerosis, 518-522
- Fluorescent antitreponemal antibody studies, in secondary syphilis, 174
- Fluorochrome reagents, in CNS SLE studies, 459
- FMLP, *see* N-Formyl-methionyl-leucyl-phenylalanine
- Follicle stimulating hormone (FSH), 1242, 1243, 1285
- Follicular phase of menstrual cycle, 1285
- Forestier's disease, disappearing lumbar hyperostosis in, 799-802
- N-Formyl-methionyl-leucyl-phenylalanine, in superoxide generation, 755-761
- Fresh red blood cells, cross-reactivity of, with neurons, 315-316
- Freund's adjuvant
 - collagen-induced arthritis and, 349-350
 - modified, 342
- Frostbite injury
 - arthritis after, 1082-1087
 - stages of, 1086
- FSH, *see* Follicle stimulating hormone
- Furosemide, in management of scleroderma, 1133

G

- GAG synthesis, *see* Glycosaminoglycan synthesis
- Gamma globulin, vs. IgG concentrations, 141-143
- Gamma globulin-minus-IgG values, for blood sera, 142-143
- Gangrene, and plasmapheresis, 1149-1150
- Gastrointestinal bleeding
 - aspirin and, 376
 - deaths from, 766
- Gastrointestinal mucosa, direct visual observation of, 382
- Gastrointestinal system sclerosis, in MCTD, 429
- Genes, 1154, 1172
 - recessive male-determining, 1204-1206
- Genetic resistance to bone marrow transplantation, 1238, 1239
- Genetics of H-Y antigen expression and function, 1204-1207
- Genital differentiation, 1278
- GH, *see* Growth hormone
- Giant cell arteritis
 - cellular immunity in, 740-744
 - in elderly black women, 202-203
 - polymyalgia rheumatica and, 277
- Glanzmann's thrombasthenia, hemarthrosis and, 1390-1393
- Glomerular lesions in cyclophosphamide therapy, 1340
- Glomerulonephritis, 1189
 - defective reticuloendothelial system Fc receptor in, 618
 - focal and mesangial, 1021
 - in hypocomplementemic urticarial vasculitis, 1024-1028
 - poststreptococcal, 405
 - prevention in New Zealand mice, 1338
 - in RA, 1018-1022
 - in SLE, 305
 - occurrence of Sm antibodies in 1334-1337
 - type C oncornavirus in, 845
 - type II interferon and, 606-607
- Glucocorticoid receptor sites, 1250-1254
 - in rat thymus cells, 1248-1249
- Glucocorticoid sensitivity of mitogen-stimulated lymphocytes, 1251-1252
- Glucocorticoids and immune responses, 1246-1256
- Glucose
 - and rheumatoid and nonrheumatoid fibroblasts, 874-875
 - synovial permeability to, 691-692
- Glucose metabolism, inhibitors of, 757
- Glucose transport, 1248
 - inhibition of, 1250
- Glucose uptake, by fibroblastic cells, 871-876
- Glucuronide as measure of estrogen metabolism, 1195
- Glutamic-oxaloacetic acid transaminase, myositis and, 210-213
- ³H-Glycine uptake, Thiotepa and, 582
- Glycoprotein biosynthesis, by scleroderma skin fibroblasts, 625-626
- Glycoprotein as C1 inhibitor, 1296
- Glycosaminoglycan synthesis
 - in dog articular cartilage, 751-753
 - explant assay of, 67
 - lymphokine-mediated suppression of, 66-70
 - by rheumatoid and nonrheumatoid fibroblastic cells, 871-876
 - suppression of, by nitrogen mustard and Thiotepa, 583
- Glycosaminoglycans
 - and articular cartilage, 1102
 - metabolism of, 748-751

Glycosaminoglycans (continued)

- refeeding cultures and, 874-875
- regeneration, 67
- Glycosphingolipidosis, in Fabry's disease, 781
- Goat antirabbit immunoglobulin, BSA articular cartilage and, 362
- Gold, *see also* Chrysotherapy
 - in RA management, 922-924
 - suppression of neutrophil function by, 660
 - therapeutic effectiveness of, 884
 - toxicity of, 108-109, 423, 497-500, 594, 645, 923
- Gold compounds, inhibition of mitogen-induced immunoglobulin by, 651
 - see also* Chrysotherapy
- Gold nephropathy, 594
- Gold sodium thiomalate
 - alterations of mononuclear phagocytes by, 1352-1360
 - vs. auranofin, 636
 - half-life of, 1418-1419
 - in proteoglycan release, 879
- Gonadal differentiation, 1275
- Gonadectomy, 1219, 1220
 - effect on immune response, 1221
- Gonadotropin control of fetal ovary, 1275
- Gonadotropins and ovarian development, 1242-1243
- Gonad-specific H-Y receptor sites, 1207, 1215
- Gonococcemia, 23
- Gonorrhea, 21
- Goodpasture's syndrome, 197, 408
- GOT, *see* Glutamic-oxaloacetic acid transaminase
- Gout
 - colchicine toxicity and, 103
 - CPPD crystals in, 428
 - diagnosis through urate crystals, 559-560
 - monosodium urate crystals in, 559-560, 672
 - reaction of bursa in, 1361-1364
 - relative frequency of, 428
 - in RA, 81-86, 939-940
 - Ticrynafen and, 677-678
 - uric acid excretion in, 98-99
- Gouty arthritis *see also* Arthritis; Gout
 - analgesics in, 103
 - fenoprofen vs. phenylbutazone in, 425-426
 - urate and, 735
- GR, *see* Genetic resistance to bone marrow transplantation
- Graft rejection, 1252, 1268-1269
- Graft-versus-host disease, scleroderma-like changes in, 904
- Graft-versus-host reaction, in pregnancy, 1302
- Grafts, osteoarticular, 1093
- Granulocytosis, in psoriatic arthritis, 657
- Granulopoiesis and erythropoiesis, effect of androgens on, 1221
- Growth hormone (GH), 1242, 1243
- Guidelines for special issues of *Arthritis and Rheumatism*, 1063

H

- ³H thymidine, 1252
- H-2 antibodies, 1301
- HA crystals, *see* Hydroxyapatite crystals

- Hageman factor activation of monosodium urate crystals, 612
 see also Factor XII
- Hageman factor dependent proteolytic enzyme pathways, 1296
- HAR, see High androgen responder males
- Hashimoto's thyroiditis, 535
- Hawaiian ethnic group, SLE frequency in, 328-332
- HBcAg, see Hepatitis B core antigen
- HBsAg, see Hepatitis B e antigen
- HBO, see Hyperbaric oxygen
- HBsAg, see Hepatitis B surface antigen
- HBV, see Hepatitis B virus
- HCG, see Human chorionic gonadotrophin
- HCS, see Human chorionic somatomammotrophin
- Heart block
 maternal rheumatic disease and, 656
 in MCTD, 679-680
- Heart disease and polymyositis, 1088-1092
- HeLa cell polymers, tritiated, 463-464
- HeLa cell ribosomes, 465-466
- Helper cell, in antiDNA antibody production, 655
- Hemagglutination
 antibody vs. extractable nuclear antigens in, 557
 inhibition of, 400
- Hemagglutination studies on human red blood cells, 348
- Hemarthrosis, Glanzmann's thrombasthenia and, 1390-1393
- Hematologic parameters, 1190-1191
- Hematopoietic stem cells, 1222, 1228
- Hematopoietic tissue, estrogen effects on, 1235
- Hemiparesis, effect on RA, 1419-1420
- Hemodialysis
 and chronic renal disease, 1263-1264
 and hepatitis B virus, 1267-1269
- Hemoflagellate kinetoplasts, in SLE diagnosis, 205-207
- Hemophilia, total knee arthroplasty in, 613
- Hemophilic-like arthropathy, and Glanzmann's thrombasthenia, 1390-1393
- Hemophilus influenza*, pseudopodagra from, 681-683
- Hepatic disease and estrone, 1287
- Hepatitis B core antigen (HBcAg), 1260, 1271
- Hepatitis B e antigen (HBeAg), 1260
- Hepatitis B surface antigen (HBsAg), 1260-1262, 1268, 1270-1271
 carriers, 1261-1262
 and hepatitis during pregnancy, 1262
 and reduced fertility, 1264
- Hepatitis B virus, 1258, 1260, 1267, 1270
 and hemodialysis units, 1269
 markers, 1270
 in parents, and secondary sex ratio of offspring, 1264-1266
 related particles, 1259
 sex differences in response to, 1250-1273
 and sex of donor and recipient in kidney and marrow transplantation, 1267-1273
 transmission from parent to child, 1262
- Hereditary angioedema and sex hormones, 1295-1299
- Hereditary defects in androgen action, 1279-1282
- Hermaphroditism, 1208
- Hexosamine, depletion of articular cartilage, 1117-1121
- Hexuronate, guanidine HCl and, 157
- High affinity androgen receptor, absence of, 1281
- High androgen responder males (HAR), 1218, 1227, 1228
- Hip arthroplasty, in JRA, 602
- Histiocytoma, in New Zealand mice, 1340
- Histocompatibility antigen, 1201
- Histocompatibility complex, major, 1156
- Histologic differentiation of testes, 1277
- HL-60 cells, 1253
- HLA antigens
 in ankylosing chondrocalcinosis, 928-932
 in kidney transplantations, 167
 in mixed cryoglobulinemia, 1009
 in psoriasis and psoriatic arthritis, 610
- HLA complex, 1303, 1304
- HLA expression by variant Daudi cell, 1213-1214
- HLA-A antigens, in dermato- and polymyositis, 622
- HLA-B8 antigen
 in celiac disease, 373
 cutaneous lupus erythematosus and, 612
 in Sjögren's syndrome, 373
- HLA-B27 antigen
 in ankylosing spondylitis, 302, 366
 in juvenile chronic arthritis, 589
 in kidney transplantations, 167
 in multiple sclerosis, 373
 and post-salmonella Reiter's syndrome, 1141-1142
 in sacroiliitis, 303-304
 in SLE associated with amyloidosis, 555
- HLA-D locus typing
 in ankylosing spondylitis and Reiter's syndrome, 371-374
 in JRA, 503
- Hormonally altered subjects, immune response in, 1219-1221
- Hormone changes during menstrual cycle, 1284-1285
- Hormone endocrinology, 1173
- Hormone-receptor complex formation, 1249-1250
- Hormones
 and autoimmunity, 1162-1176
 effect on autosomal and X-linked genetic control of antibodies, 1177-1178
- Human adjuvant disease, 532-536
 characteristics of, 534-535
- Human chorionic gonadotrophin (HCG), 1285
- Human chorionic somatomammotrophin (HCS), 1303
- Human H-Y antigen, testis-organizing function of, 1211-1216
- Human granulocyte factor, in DNA synthesis, 641-642
- Human helper T cell function, inhibition of, 636
- Human leukocytes, phagocytic process in, 728-835
 see also Leukocytes
- Human monocytes, collagenase-stimulating factor production by, 604
 see also Monocytes
- Human peripheral blood neutrophils, penicillamine and, 643
- Human red blood cells, hemagglutination studies in, 348
 see also Erythrocyte enzymes; Erythrocytes
- Human rheumatoid cells, implantation of in mice, 595-596
- Human spleen extract, as antigen source, 797
- Human trophoblast layers from term placentas, Ig in, 1310
- Humerus, fatty lesions of following corticosteroid treatment, 199-200
- Humoral substances in immunosuppression during pregnancy, 1302-1304
- HuNTA, see T lymphocytotoxic autoantibody

- H-Y antigen, 1199-1216
 and development of mammalian testis, 1200-1210
 excretion by variant Daudi cell, 1214-1215
 phylogentic conservation of, 1201
 in primary sex determination, 1201-1202
 serologic assay for, 1200-1201
 in skin grafts, 1200
 testis-organizing function of, 1211-1216
- H-Y compatibility, 1270
- H-Y genes, location of, 1204
- H-Y transplantation antigen and major histocompatibility complex cell surface antigens, 1207
- Hyaluronic acid
 proteoglycans and, 508
 superoxide radical and, 616
- Hyaluronic acid synthesis, 662
- Hyaluronidase, in synovial fluid samples, 979
- Hydralazine, in management of scleroderma, 1133
- Hydrocortisone
 inhibitory effect of, 883
 lysosomal membranes and, 883
 in New Zealand mice, 1341
 in proteoglycan release, 878-881
 superoxide generation and, 755
 in synovium cocultures, 877
- Hydrocortisone sodium succinate, 669
- Hydroxyapatite crystals, identification in synovial fluid, 389-395
- Hydroxychloroquine
 in DNA synthesis, 268
 ocular toxicity and ophthalmologic safety of, 832-835
 in SLE, 324
- 16 α -Hydroxysterone
 and cirrhosis, 1198
 in SLE, 1197, 1198
- Hydroxylation in SLE, 1196-1198
- 17 α -Hydroxyprogesterone secretion by ovary, 1285
- Hydroxyproline
 in proteoglycan aggregation, 161
 in skin thickening, 135, 138-139
- Hydroxyproline factors, protein-bound, 650
- 3 β -Hydroxysteroid dehydrogenase synthesis, 1277
- Hyperbaric oxygen
 inhibiting effect of, 336
 in rat adjuvant arthritis, 334-339
 therapeutic effects of, 336
- Hyperdiploidy, 1185
- Hypergammaglobulinemia, polyclonal, 915
- Hyperglobulinemia, in systemic sclerosis, 623
- Hyperglobulinemic purpura, 141
- Hypernephroma, and SLE, 1396-1398
- Hyperostosis, diffuse idiopathic skeletal, 801
- Hypersensitivity vasculitis, in acute monocytic arthritis, 297
- Hyperuricemia, Ticrynafen in, 667-678
- Hypocomplementemia, in mixed cryoglobulinemia, 1009
- Hypocomplementemic urticarial vasculitis, glomerulonephritis and pseudotumor cerebri in, 1024-1028
- Hypogammaglobulinemia, X-linked, 71-75
- Hypomagnesemia, 1122, 1125-1126, 1128-1130
- Hypothyroidism, pseudogouty arthritis in, 1416-1417
- Hypoxanthine, conversion to xanthine oxidase, 251, 257
- Hypoxanthine-guanine phosphoribosyltransferase, 529
- HyPro, proteolytic activity and, 255-256
- ## I
- Ibuprofen
 in acute renal failure, 281-284
 in superoxide inhibition, 755
- IC, *see* Immune complexes
- Idiopathic edema
 in nonarticular rheumatism, 396-399
 "posture test" in, 397-398
- Idiopathic inflammatory muscle disease, *Toxoplasma gondii* antibodies in, 209-214
see also Polymyositis
- IE, *see* Idiopathic edema
- IgG
 fractions of low-pH eluates, 1311
 peaks, 1163, 1165-1166, 1168
- IgG anti-brain antibodies
 in SLE, 674
 in SLE-associated CNS dysfunction, 458-462
- IgG anti-DNA rheumatoid factor complexes, 625
- IgG autoantibodies, 988
- IgG concentration, gamma globulin and, 141-143
- IgG immunoglobulin
 Fc binding of to nervous tissue structures, 1-5, 318
 in immune renal disease, 405
 Lyme arthritis and, 971-982
 in myositis, 213
 polymerization of, 141-143
- IgG rheumatoid factor, 141, 648, 988-997
- IgM rheumatoid factor and, 993-994
- ingestion of, 939
- in MRL/1 mice, 1074, 1080
- radioimmunoassay of, 990-992
- self-association of, 642
- IgM anti-neuroblastoma antibodies, in extra-CNS disease, 457-460
- IgM peaks, 1163, 1168
- IgM rheumatoid factor, 993-994
- IgM staining, of neuroblastoma cells, 461
- ¹³¹I-HSA, *see* Radioiodinated albumin
- Imaginal disks, 1158
- Immobilized canine knee, proteoglycan aggregation defect in, 508-517
- Immune complexes, 1304
see also Circulating immune complexes
 Clq binding of in Felty's syndrome, 697-701
 comparison of immunoassays for, 433-438
 decreased complement solubilization, 642
 in disseminated gonococcal arthritis-dermatitis syndrome, 19-23
 interaction with polymorphonuclear leukocytes in cartilage, 1416
 isolation of, 617
 in MRL/1 mice, 1074, 1079-1080
 and plasmapheresis in RA, 1149, 1150
 polymorphonuclear leukocyte interaction with, 353-364
 release of in SLE, 639
 surface-bound, 649
 in synovial fluids, 440-447
- Immune renal disease, *see also* Renal disease; Renal failure

- Immune renal disease (continued)*
 complement activation in, 403-404
 and deposition of β 1H globulin in kidneys, 403-410
 IgG immunoglobulin in, 405
- Immune response**, 1272
 androgen sensitivity in sex differences as factor in, 1218-1233
 cell mediated, in adjuvant arthritis, 1365
 differentiation of, 1217-1256
 effect of androgen on, 1227, 1228
 effect of estrogen on, 1219
 and glucocorticoids, 1246-1256
 to nucleic acids and sex hormones, 1171
 ribavirin treatment and, 145-150
 and sex hormones, 1172
 sex hormones and pregnancy, 1274-1313
 to type II collagen, 1347
 to viruses, 1257-1273
- Immune response gene**, X-linked, 1180
- Immune surveillance**, 1156
- Immune system**, chrysotherapy and, 309-310
- Immunization with ssDNA**, 1172
- Immunoassays**, comparison of, in RA, 433-438
- Immunoblastic lymphadenopathy**
 conflicting symptoms in, 913-914
 Sjögren's syndrome and SLE features in, 911-915
- Immunoblastic sarcoma**, 911-915
- Immunodiffusion studies**, CTAP-III and, 269
- Immunoelectron microscopy studies**, of polymorphonuclear leukocyte interactions with immune complexes in joint collagenous tissues, 357-358
- Immunoenhancement**, 1221-1222
- Immunofluorescence assays**
 complement C3 binding in, 565
 conventional, 565-570
 of T cells and anti-T cell antibodies in SLE, 114-121
- Immunoglobulin-containing inclusion**, phagocytosis of, 630
- Immunoglobulin production**, gold compounds and, 651
- Immunoglobulins**
 acid elution from renal cortex homogenates, 861-862
 complement and, in Lyme arthritis, 475-476
 effect of androgen on, 1224
 in human trophoblast layers from term placentas, 1310
 and trophoblasts, 1311-1312
- Immunologic regulation in pregnancy**, 1300-1307
- Immunosuppression**
 humoral substances during pregnancy, 1302-1304
 produced by androgen, 1220
- Immunosuppressive activity of alpha-fetoprotein**, 1303
- Immunosuppressive therapy**, in New Zealand mice, 1338-1343
- Inactivation of X chromosome**, 1261-1262
- Index**, Ritchie Camp articular, 1056
- Indomethacin**
 antibody rebound and, 707
 effect on adjuvant arthritis, 1372
 prostaglandin system and, 883-884, 1109, 1114
 in protein and collagen synthesis, 604
 in proteoglycan release, 878
 in superoxide inhibition, 755
 in synovium cocultures, 877
- Indomethasone**, in DNA synthesis, 268
- Infants**, polyarteritis nodosa in, 821
- Infection in SLE patients**, 1326-1333
 immunization to pneumococcus, 1321-1325
- Inflammation**
 chronic, 1378-1379
 mycoplasma infections as models of, 1375-1381
 of superficial bursa, 1361-1364
- Inflammatory arthritis**, polymorphonuclear leukocyte accumulation in, 258
- Inflammatory bowel disease**
 in children, 645
 spondylitis and, 607
- Inflammatory muscle disease**, *Toxoplasma gondii* antibodies in, 209-214
- Influenza**, vaccination against in SLE, 1321-1325
- Inhibition of phagocytosis by glucocorticoids**, 1253
- Inorganic pyrophosphate**
 from CPPD crystals, 392-393
 extrusion of in dog and rabbit hyaline, 653
 measurement of in osteoarthritis and CPPD, 886-894
 quantification variables in, 654
- Inosine**, 529
- Interaction of serum**, in MRL/1 mice, 1074-1081
- Interferon**
 in mouse glomerulonephritis, 606-607
 properties of, 1377-1378
- Internal genitalia**, differentiation of, 1278
- Interstitial cells of Leydig**, 1288
- Intestinal bypass surgery**, systemic immune complex disease following, 688
- Intravascular coagulation**, in polymyalgia rheumatica, 616
- Intrinsic clotting system**, 1137
- 5-Iodo-2-deoxuridine (IUdR)**, 1238
- Ischemic pancreatic disease**, synovial fat necrosis and, 547-553
- IUdR**, see 5-Iodo-2-deoxuridine
- Ixodes scapularis**, 471

J

- Jejunioleal bypass**
 arthritis associated with, 711-717
 clinical characteristics in, 712
 cryoglobulins in, 717
 HLA-B27 antigen in, 716
 immunologic features in, 714, 717
- Joint collagenous tissues**, polymorphonuclear leukocyte interaction with immune complexes in, 353-364
- Joint effusions**, following kidney transplantations, 164-168
- Joint lavage**, and CPPD crystals 1122, 1127
- Joint resurfacing**, 1093, 1102
- Journals**, rheumatology, 1053
- JRA**, see Juvenile rheumatoid arthritis
- Juvenile ankylosing spondylitis**, 593
 see also Ankylosing spondylitis
- Juvenile chronic arthritis**, HLA-B27 antigen in, 589
- Juvenile dermatomyositis**, 661
- Juvenile rheumatoid arthritis**, see also Rheumatoid arthritis
 antinuclear antibodies in, 502
 aspirin in, 826-830
 hidden rheumatoid factor in, 639-640
 hip arthroplasty in, 602
 HLA typing in, 503

Juvenile Rheumatoid Arthritis (continued)

- immunologic and clinical associations of C3 split products in, 502-507
- immunologic assays in, 503-504
- orthodontic/surgical therapy in, 641
- pharmacokinetic monitoring in, 826-830
- polyarticular, 506
- salicylate-related liver chemistry and, 592
- serologic abnormalities in, 505
- SLE and, 602-603
- subgroups of, 507
- T cell cytotoxic antibodies and, 128
- Juvenile rheumatoid arthritis antibody reactive T cells, PHA and, 128

K

- Kallikrein inhibitor, 1295
- Kawasaki disease, 596
 - clinical manifestations of, 614
 - salicylate therapy in, 621
- Keratitis sicca, 522
- Kidney, immunologic studies in SLE, 864-869
- Kidney and bone marrow transplantation, HBV and sex of donor and recipient, 1267-1273
- Kidney graft survival, 1268
- Kidney transplantation, 1267-1273
 - and HBV infection, 1270
 - HLA status in, 167
 - joint effusions following, 164-168
 - radiographs and bone scans following, 166-167
 - synovial fluid analysis following, 165-166
- Kinetoplasts, hemoflagellate, 205-207
- Klinefelter's syndrome, 429
 - and SLE, 1195, 1198
- Knee
 - artificial, 1043
 - meniscectomy of, 177-180
 - osteopenia of, 178
 - reflex sympathetic dystrophy syndrome of, 177-180
 - steroid-associated necrosis of, 624
- Knee arthritis, 626
- Knee effusions, following transplantation, 166-168
- Knee prosthesis, total, 626
- Knee surgery, in RA, 880
- Kniest syndrome, 286-289
- Kyphoscoliosis, 286

L

- Lactate dehydrogenase
 - myositis and, 210
 - urate in release of, 732
- Lactation and pregnancy, thymic function during, 1292
- Lavage of joints and CPPD crystals, 1122, 1127
- LCA, *see* Cold-reactive lymphocytotoxic antibodies
- LDH, *see* Lactate dehydrogenase
- LE (lupus erythematosus) cells, in pleural fluid, 936-937, *see also* Systemic lupus erythematosus
- Legionnaire's disease, 806
- Leishmania organisms, in SLE diagnosis, 205-206

- Leprosy, 1263
 - exudative arthritis in, 593
 - inflammatory arthropathy in, 587
- LETS protein, 983, *see also* Fibronectin
- Leukocytes
 - phagocytic process in, 728-735
 - tissue thromboplastin-like procoagulant activity of, 652
- Levamisole
 - and alteration of lymphocyte function in New Zealand mice, 236-241
 - in cell-mediated response, 236-241
 - cyclic nucleotides and, 240-241
 - defined, 236
 - pneumococcal polysaccharide and, 237-241
- Light, Alvin, 1047
- Lipopolysaccharide (LPS), 1192, 1193
 - response, 1191
- Listeria monocytogenes*, as cause of arthritis, 1139-1140
- Listeriosis, 1139-1140
- Liver cancer and HBV-associated chronic liver disease, 1271
- Local immunosuppressants, placental steroid hormones as, 1304-1305
- Low-affinity platelet factor, 4, 261
- Low complement level, renal involvement and, 234
 - see also* Complement
- Low-pH eluates, 1310, 1311
- LPS, *see* Lipopolysaccharide
- Lumbar hyperostosis, in Forestier's disease, 799-802
- Lupus, *see* Central nervous system lupus erythematosus; Discoid lupus erythematosus; Systemic lupus erythematosus
- Lupus anticoagulant, 1135
- Lupus band tests, azathioprine and, 868-869
- Lupus erythematosus, subacute cutaneous, 660
- Lupus glomerulonephritis
 - immunologic studies of, 864-869
 - mortality in, 764-768
 - "Lupus-like" syndromes, cold-reactive lymphocytotoxic antibodies in, 1060-1063
- Lupus nephritis, *see also* Systemic lupus erythematosus
 - β -IH deposition in, 406
 - mortality in, 764-768
 - ribavirin in, 150
- Luteal phase of menstrual cycle, 1285
- Luteinizing hormone, 1242-1243
 - peak, 1285
- Lyme arthritis, 471-482
 - agent/antigen tests for, 477-478
 - caustic agent in, 480
 - clinical characteristics of, 473-475
 - cryoglobulins and immunoglobulins in, 474-475, 478-481
 - cryoprecipitate protein in, 478
 - defined, 471
 - immunoglobulins and complement in, 475-476
 - immunologic and immunogenetic markers in, 662-663
 - joint fluid in, 476
 - monocytes in, 300
 - recurrent attacks of, 481-482
 - remissions in, 481-482
 - tick transmission of, 482
- Lymph node cells, 1192
 - and natural killer cells, 1236
- Lymphadenopathy, 1191
 - anti-DNA and, 324

Lymphadenopathy (continued)

- immunoblastic, 911-915
- syphilis and, 171
- Lymphapheresis
 - clinical effects in RA, 1055-1059
 - procedure for, 1057-1058
- Lymphoblastic cell lines
 - in Epstein-Barr virus and SLE studies, 844-848
 - RA and, 643-644
- Lymphoblastoid cells
 - cytoplasmic blebs and budding particles from, 848-851
 - extracellular particles in, 853
 - herpes virus particles in, 852
- Lymphocyte cultures, PHA stimulation of, 60
- Lymphocyte function, alteration of in New Zealand mice, 236-241
- Lymphocytes, 1156, 1158-1159, 1247
 - activation by mycoplasmas, 1377
 - antineuronal antibody cross-reactions with, in SLE, 313-319
 - infiltration after thymectomy, 1242
 - removal of, 1055-1059
 - thoracic duct drainage, 1405-1412
- Lymphocytotoxic antibodies, in SLE, 460, 1060-1063
 - assay for, 1064-1073
- Lymphoid cells, 1248
- Lymphoid irradiation, 631-632
- Lymphoid neoplasms, cytotoxic agents in, 938
- Lymphokine, rheumatoid lymphocytes and, 614
- Lymphokine-mediated suppression, of chondrocyte glycosaminoglycan synthesis, 66-70
- Lymphoma, in New Zealand mice, 1338-1343
- Lymphomyeloid system, effect of sex steroids on, 1220-1221
- Lymphoplasmapheresis, 670
 - in RA management, 703-709
- Lymphoproliferation and Y chromosomes, 1188-1194
- Lymphotoxin, in glycosaminoglycan synthesis, 70
- Lyonzation, 1261

M

- M cells, *see* Marrow-dependent cells
- MA antigen, characteristics of, 675
- MAD, *see* Monoacetyl dapsone
- Major histocompatibility complex (MHC), 1156-1157, 1207
- Major histocompatibility genes, autoantibody production of, 616
- Male cell surface antigen, 1267, 1269
- Male-determining genes, 1204
- Male hormones as immunosuppressants, 1219
- Male phenotype, fetal testis hormone effects on, 1279
- Male pseudohermaphroditism, 1202
- Male-specific cell surface component, 1200
- Male-specific histocompatibility antigen, 1201
- Malignant hypertension, arrest or reversal of, 603
- Mammalian testis and H-Y antigen, 1200-1210
- Mannitol, superoxide and, 255
- "Manure shoveler's hip," 940-941
- Marfan's sign, 542, 545, *see also* Congenital contracture arachondactyly
- Master gland of immunity, 1241
- Mating preference, 1157
- Mayo Clinic, ankylosing spondylitis epidemiology in, 365-369
- MBGG, *see* Methylated bovine gamma globulin
- MCR, *see* Metabolic clearance rate
- MCTD, *see* Mixed connective tissue disease
- 2-ME, sensitivity of anti-ssDNA antibodies to, 1182
- Mechlorethamine, 579
- Medical students
 - knowledge of rheumatology by, 290-293
 - "minimum acceptable performance" by, 293
- Membranolysis, in pseudogout, 637
- Mendelian recessive disorder, 1296
- Menisectomy, reflex sympathetic dystrophy syndrome of knee following, 177-180
- Menstrual cycle, 1284-1285
 - estradiol in, 1290
- Menstrual period, angioedema during, 1296
- Metabolic clearance rate (MCR), 1289
- Metaphase chromosomes, 1212
- Metatarsophalangeal joints, urate crystals in, 559-560
- Metazoa, 1156
 - as cellular differentiation, 1153
- Metazoan evolution, 1155, 1157
- Methylated bovine gamma globulin (MBGG), 1171
- Methyldopa, in management of scleroderma, 1133
- Methylprednisolone pulse therapy, in SLE, 629
- Methyltestosterone, 1296
- MHC, *see* Major histocompatibility complex
- Meticortelone, 575
- MF, *see* Mycosis fungoides
- MFA, *see* Modified Freund's adjuvant
- MICC, *see* Mitogen-induced cellular cytotoxicity
- Mice, *see* BSXB mice; MRL/l mice; New Zealand mice
- Microcrystalline monosodium urate, 718
- Microfilariae, intraarticular, in laboratory animals, 1142-1145
- Migration inhibition factor (MIF), 1304
- Minoxidil, in management of scleroderma, 1133
- Mithramycin
 - dosage in, 217-218
 - followup studies for, 216
 - in Paget's disease of bone, 215-218
- Mitogen, sensitivity and glucocorticoid receptors, 1250-1252
- Mitogen-induced cellular cytotoxicity, 59
 - inhibition of in SLE patients, 62
 - as in vitro model of lymphocyte function, 63
- Mitogen-responsive T cells, HuNTA and, 126
- Mitogen-stimulated lymphocytes, glucocorticoid sensitivity of, 1251-1252
- Mitogenesis, dexamethasone-induced inhibition, 1253
- Mitomycin C, and DNA synthesis, 1112, 1114
- Mixed connective tissue disease (MCTD)
 - arthropathy of, 50
 - articular manifestations of, 43-51
 - circulating immune complexes in, 484-488
 - clinical discriminators in, 675-676
 - and cold-reactive lymphocytotoxic antibodies, 1060-1063
 - complete heart block in, 679-680
 - destructive changes in, 48
 - gastrointestinal systemic sclerosis in, 429
 - hands and wrists in, 46-47
 - mutilans-like arthropathy in, 1013-1017
 - osteoporosis and, 46

Mixed connective tissue disease (continued)

- pregnancy risk in, 627
- rheumatoid factor in, 48–50
- RNP antibodies in, 1334
- subcutaneous nodules in, 46
- as subset of SLE, 488
- synovial fluid analysis in, 48–49
- synovitis in, 44
- Venn diagram of correlation in, 485–487
- Mixed cryoglobulinemia, 618
 - complement component depletion in, 1006–1011
- Mixed lymphocyte culture, Ir loci coding and, 371
- Mixed lymphocyte reaction (MLR), 1312
 - autologous, 770–775
 - syngeneic, 772
- Model, animal, *see* Adjuvant arthritis; New Zealand mice; MRL/l mice
- Modified Freund's adjuvant, 342
- Molecular communication circuits, 1156–1157
- Molecular specificities, 1157
- Moloney virus-induced T cell lymphoma, 1234
- Monarthritis, septic, due to *Listeria monocytogenes*, 1139–1140
- Monoacetyl dapsone, in SLE, 778
- Monoclonal rheumatoid factor, 698
- Monoclonal rheumatoid factor binding assay, 441
- Monocyte cytotoxicity, defective, 591
- Monocyte-depleted populations, 492–493
- Monocyte macrophage process, activation of, 492–493
- Monocytes
 - antibody-dependent cell-mediated cytotoxicity by, in RA, 490–493
 - in progressive systemic sclerosis, 637
 - and surface-based immune complexes, 649
- Monocytosis, *see* Synovial fluid monocytosis
- Mononuclear cells, in PHA-induced cellular cytotoxicity, 59
- Mononuclear phagocytes (MΦ) alterations by gold compounds, 1352–1360
- Monosodium urate monohydrate crystals, 390–394
 - C3 activation by, 571–577, 612, 620
 - effect of EDTA and EGTA on, 574–575
 - in gout, 672
 - Hageman factor activation of, 612–613
 - heating of, 573, 575
 - microcrystalline, 718
 - in polymorphonuclear interaction studies, 354–356
 - as spherulites, 608
- Moraxella kingii*, 1040
- Mosaicism in XX true hermaphroditism, 1203
- MΦ, *see* Mononuclear phagocytes
- MRF-BA, *see* Monoclonal rheumatoid factor binding assay
- MRL/l mice, serum-serum interactions in, 1074–1081
- mRNA, 1246, 1249, 1279, 1291
- MSUM, *see* Monosodium urate monohydrate
- Mucocutaneous lymph node syndrome, 596, 823–824
- Mullerian inhibition factor, 1202
- Mullerian regression factor, 1275, 1279
- Multiple sclerosis, ankylosing spondylitis and, 784–785
- Multipurpose arthritis centers, 1051

- Murine leukemia viruses, 1193
- Murine lupus nephritis
 - immunosuppressive agents in, 151
 - ribavirin and, 150
- Musculoskeletal complaints following kidney transplantation, 164–165
- Musculoskeletal effects, of secondary syphilis, 174–175
- Mutations
 - in chronic hepatitis and cirrhosis, 1272
 - in 5α-reductase enzyme, 1280
- Mutilans-like arthropathy, in MCTD, 1013–1017
- Myasthenia gravis, penicillamine-induced, 197
- Mycobacteria, as cause of hand infections, 1386
- Mycobacterium butyricum*, 342
- Mycobacteria leprae* in testes, 1263
- Mycobacterium terrae*, in tenosynovitis, 1386–1389
- Mycobacterium tuberculosis*, 334
- Mycoplasma arthritidis*, 1377–1380
- Mycoplasma pneumoniae*, and arthritis, 1375
- Mycoplasma infections, as models of chronic inflammation, 1375–1381
- Mycosis fungoides, arthritis and, 424–425
- Myeloperoxidase activity, inhibitors of, 758
- Myocardial infarction, in SLE, 764
- Myochrysin, half-life of, 1418–1419
- Myopus schisticolor*, fertile XY females of, 1203–1204
- Myositis
 - complement fixation test in, 210–211
 - Toxoplasma antibodies and, 209–214
- Myxedema
 - cholesterol-laden effusions, in, 186
 - and pseudogout, 1416–1417

N

- NADPH (reduced nicotinamide adenine dinucleotide phosphate), inorganic pyrophosphate of, 888
- Nafoxidine, 1175
- Naproxen, effects on connective tissue, 1365–1374
- National Commission on Arthritis, 787
- National Health Survey (1974), 196
- National Institute of Arthritis, Metabolism, and Digestive Diseases (NIAMDD), 188
 - research support from, 1049–1052
- Native DNA antibodies
 - complement-fixing activity of, 964–966
 - in SLE, 959–966
- Natural killer (NK) cells, 1235–1236, 1238
 - and autoimmune disease, 1234
 - and bone marrow, 1238
 - effect of estrogen on, 1234–1240
 - and thymectomy, 1238
- Natural T lymphocytotoxic autoantibody, *see* Anti-T cell antibodies (NTA)
- nDNA, *see* Native DNA antibodies
- Necrotizing vasculitis, and cold-reactive lymphocytotoxic antibodies, 1060–1063

- Neisseria gonorrhea*, 20
- Neonatal thymectomy, in mice, 1241-1242
and ovarian dysgenesis, 1292
- Neoplasms, in female New Zealand mice, 1338-1343
- Nephritis, *see also* Kidney; Glomerulonephritis; Lupus nephritis
histopathologic, 405
murine lupus, 150-151
- Nerve conduction studies, in carpal tunnel syndrome, 308-309
- Neurologic diseases, cerebrospinal fluid C-GMP and, 454-456
- Neurologic events in SLE, 1382-1384
- Neuronal activity, immunologic specificity of, 316
- Neuronal pathfinding, 1159
- Neurons, cross-reactivity of with fresh red blood cells, 314-316
- Neutral protease, action on proteoglycans, 655
- Neutrophils
gold suppression by, 660
superoxide production of, 251-252, 659
- New Zealand mice
activated B cell subpopulations in, 600
anti-DNA antibodies from, 603
anti-DNA levels in, 413-415
azathioprine in, 1342
carcinoma in, 1338-1343
chondroma in, 1340
congenitally immunologically mutant, 611
cyclophosphamide treatment in, 1338-1343
danazol, effects on, 1399-1402
histiocytoma in, 1340
hydrocortisone treatment in, 1341
immunoregulation in, 412-417
immunosuppressive therapy in, 1338-1343
lymphocyte function alteration in, 236-241
lymphoma in, 1338-1343
malignancy, incidence, 1341
natural T lymphocytotoxic autoantibody in, 123-128, 1070-1071
neoplasms produced in, 1338-1343
primary B lymphocyte abnormality in, 597
proteinuria in, 147-148, 414
pulmonary adenoma in, 1338-1343
ribavirin treatment of, 145-152
sarcoma in, 1340
sex hormone modulation of autoimmunity in, 1162-1169
strontium as reducer of autoimmunity in, 657
T and B cell suppressor activity in, 416-417
thymus grafts for, 412
total lymphoid irradiation in, 631
- NHS, *see* Normal human serum
- NIAMDD, *see* National Institute of Arthritis, Metabolism, and Digestive Diseases
- Nitrogen mustard, acute metabolic effects of in rabbit articular cartilage and synovium, 579-585
- NK cells, *see* Natural killer cells
- Nonarticular rheumatism
idiopathic edema as cause of, 396-399
posture test in, 397-398
- Nonsteroidal antiinflammatory drugs, idiopathic edema and, 399
- Normal human serum
in antiDNA antibody studies, 220-224
ultracentrifugation of in immune complex studies, 444
- NTA, *see* Anti-T cell antibodies
- Nuclear acidic protein antigen, 675
- Nuclear antigens, autoantibodies to, 87
- Nuclear dexamethasone binding, 1250
- Nuclear nonhistone protein, purification of in SLE, 635
- Nuclear ribonucleoprotein particles
reactivity of with SLE serum antibodies, 467-469
in SLE antiribosomal antibody studies, 464-465
- Nucleic acids
antibodies to, 1164
immune responses to, and sex hormones, 1171
- ## O
- OA, *see* Osteoarthritis
- Oahu, SLE incidence by ethnic groups in, 328-332
- Obese postmenopausal women, estradiol in, 1290
- Obesity and estrogen levels, 1286
- Obesity, jejunoileal bypass and, 711-717
- Oncornavirus, type C, 844-855
- Ontogeny, 1153-1154
- Oophorectomy, effect on immune response, 1222
- Oral gold compounds, proteinuria as complication of, 1417-1418
- Organic brain disorders, in SLE, 317-319
- Orthostatic sodium or water retainers, 397
- Osmiophilic spirochetes, in secondary syphilis, 174
- Osteitis subacute dactylitis, 1403-1404
- Osteoarthritic cartilage
canine, 666
proteoglycan extraction from, 161-162
- Osteoarthritic hip, articular cartilage from, 635, 746
- Osteoarthritis
estradiol in, 55-56
estrogen and, 52-58
pathologic cartilage changes in, 54
proteinuria in, 667
proteoglycan aggregation in, 161-162
pyrophosphate values in, 886-894
rabbit, 155-162
salicylates and, 746
sulfate-incorporation studies and, 55-56
synovial hydroxyapatite crystals in, 389
- Osteoarticular grafts, 1093
- Osteomalacia, oncogenic, 672-673
- Osteomyelitis, rheumatic presentation of, 631
- Osteopenia, of knee, 178
- Osteophyte proteoglycan, metabolism of in osteoarthritis, 52
- Osteoporosis, 46, 180
- Ouchterlony technique, in antigen-antibody identity resolution, 796
- Ovarian dysgenesis, 1242-1243
and neonatal thymectomy, 1292
- Ovarian morphology, 1241
- Ovary, 1243
3 β -hydroxysteroid dehydrogenase synthesis in, 1277
steroid secretion by, 1285
after thymectomy, 1242
- Oxygen, hyperbaric, *see* Hyperbaric oxygen
- Oxygen generation, from psoriasis and psoriatic arthritis patients, 658
- ## P
- Paget's disease of bone, mithramycin in, 215-218
- Paganini, Niccolo, 1047

- Painful prosthetic replacement, radionuclide imaging in, 601
- Palate perforation, in Behçet's syndrome, 308
- PAN, *see* Polyarteritis nodosa
- "Pannus" formation, in rat arthritis, 35
- Parachloromercuribenzoic acid, 529
- Parental responses to HBV infection and secondary sex ratio of offspring, 1264-1266
- Parotid flow rates, 809, 814
- Partial transient osteoporosis syndrome, 180
- Patella, patchy osteopenia of, 178-179
- Pathophysiology of hereditary angioedema, 1295-1296
- PCOD, *see* Polycystic ovarian disease
- PEG, *see* Polyethylene glycol
- Penicillamine
- vs. chrysotherapy, in RA, 663
 - in DNA synthesis, 268
 - helper T cell function inhibition by, 636
 - in myasthenia gravis, 197-198
 - in peripheral blood neutrophil response, 643
 - proteinuria, 594
 - in RA, 588
 - skin reactions to, 646
 - in skin thickening, 135
 - toxicity, genetic predisposition to, 645
- Penicillin, in acute renal failure, 282-283
- Pericardial disease, in RA, 563-564
- Peripheral aromatization, 1286-1287
- Peripheral conversion of androgens to estrogens, 1286
- Peripheral estrogen, 1287-1289
- Periscapular pain, elastofibroma in, 792-795
- Persistent HBsAg⁺, 1261
- PF, *see* Plasmapheresis
- PG, *see* Proteoglycans
- PHA, *see* Phytohemagglutinin
- Phagocytic function, factors affecting, 619
- Phagocytosing human leukocyte, urate in uptake of, 730-731
- Phagolysosomes, gold precipitate content, 1359
- Phenomenon antibody rebound, 1149
- Phenotypic adaptation, 1154-1156
- Phenotypic differentiation of embryo, 1277-1279
- Phenylbutazone
- compared with fenopfen in acute gouty arthritis, 425-426
 - in DNA synthesis, 268
 - in superoxide inhibition, 755
- Phorbol myristate acetate
- induction of in rabbit synovial and collagenase production, 1109-1116
 - fibroblasts, 596
- Phylogenetic conservation of H-Y antigen, 1201
- Phytohemagglutinin, 1191-1193, 1250, 1302
- lymphocyte hyporesponsiveness to, 637
- Phytohemagglutinin-induced cellular cytotoxicity
- inhibition of, 60
 - in SLE, 59-64
- Pituitary luteinizing hormone, 1288
- Placenta, 1301, 1304
- trophoblast cells of, 1308
- Placenta-bound immunoglobulins, 1308-1313
- Placental HCG secretion, 1288
- Placental steroid hormones as local immunosuppressants, 1304-1305
- Plant thorn synovitis, thermography in diagnosis of, 1037-1038
- Plasma membrane
- H-Y antigen on, 1204
 - retention of variant Daudi cells, 1212
- Plasma prolactin levels, 1242-1243
- Plasma serum, preparation of, 262
- Plasmin, 1296
- Platelet aggregation in RA, 896-902
- Platelets
- antiheparin factor from, 261
 - connective tissue activating peptide-III from, 261-262
 - in immune complex-induced vasculitis, 901
- Pleural fluid, LE cells in, 936-937
- Pluripotential stem cells, 1221
- PM, *see* Polymyositis
- PM-1 antibodies, association with polymyositis, 1334
- PM-2 DNA antigen, 1413-1415
- PMA, *see* Phorbol myristate acetate
- PMR, *see* Polymyalgia rheumatica
- Pneumococcal polysaccharide
- effects on SLE, 1321-1325
 - levamisole and, 237-241
 - spleen cell antibody responses to, 239-240
- Pneumocystis carinii*, 767
- Pneumovax, use in SLE patients, 1321-1325
- Pokeweed mitogen, in X-linked hypogammaglobulinemia and chronic polyarthritis, 71-75
- Polled gene, 1204-1205
- Polyarthralgias, syphilis and, 171
- Polyarteritis nodosa
- in childhood, 820-824
 - leukocytosis in, 822
 - mucocutaneous lymph node syndrome and, 823-824
- Polyarthritis
- acute monocytic arthritis and, 298-300
 - chronic, 71-75
 - monocytosis and, 294-298
 - recent onset, 665
 - following rubella infection, 400
 - Takayasu's arteritis and, 687
 - vitreal collagen and, 347
- Polycystic ovarian disease, 1286-1287
- Polydactylitis, symmetrical, 1403-1404
- Polyethylene glycol, in antiDNA antibody studies, 220-224
- Polychondritis, relapsing, 102-103, 204
- Polymorphonuclear leukocytes (PMN)
- accumulation of in joint spaces, 258
 - horseradish peroxidase-conjugated antirabbit Ig and, 361
 - interaction with immune complexes in cartilage, 1416
 - interaction with immune complexes in joint collagenous tissues, 353-364
 - plasma factors and, 708
 - quantitation of, attached to articular surfaces, 354-359
 - superoxide and, 251
- Polymyalgia rheumatica
- cellular immunity and, 740-744
 - defined, 277
 - electromyographic findings in, 277-280
 - E-rosette-forming cells in, 742
 - giant cell arteritis and, 277

- Polymyalgia rheumatica (continued)*
intravascular coagulation in, 616
- Polymyositis**
cardiac involvement in, 1088-1092
PM-1 antibodies in, 1334
precipitating antibody systems in, 643
Toxoplasma gondii antibodies in, 209-214
- Polymyositis-dermatomyositis, definition of, 1088, 1091
- Polynucleotide antigens, reactivity of anti-cytoplasmic ribosomal antibodies with, 467-468
- Polyphosphates, inorganic, 341
^{99m}Tc-polyphosphates, in sacroiliac joint scintigraphy, 893
- Population dissection, in laboratory data analysis, 840
- Postnecrotic cirrhosis, 1262
- Post-receptor resistance, 1280, 1282
- Postrubella vaccination arthritis, 667
- "Posture test," in nonarticular rheumatism, 397-398
- PPD, *see* Purified protein derivative
- Precipitating autoantibodies, identification of, 797
- Prazosin, in management of scleroderma, 1133
- Prednisolone, in adjuvant arthritis, 1372
- Prednisone**
antibody rebound and, 707
in aseptic meningitis, 453
cerebrospinal fluid C-GMP levels and, 451
and lymphocyte subpopulations in SLE, 4-5
mixed leukocyte culture suppression by, 617
- Pregnancy**
and B cells, 1219
angioedema during, 1296
antinuclear factor and antiDNA in sera, 201-202
DHEAS in, 1286
HBsAg⁺ hepatitis in, 1262
immunologic regulation in, 1300-1307
immunosuppression during, 1302-1304
and lactation, thymic function in, 1292
in MCTD, 627
sex hormones and immune response, 1274-1313
SHBG in, 1289
and T cells, 1219
weakening of material cellular immunity in, 1302
- Pregnenolone conversion to androstenediol, 1277
- Preliminary Criteria for the Classification of Systemic Lupus Erythematosus, 917-921
- Prepubertal castration effects on antibodies, 1167, 1179
- Preservation of articular cartilage, 1093-1108
- Presidential address to the American Rheumatism Association, 1041-1054
- Primary care physician, continuing education in RA for, 787-791
- Primary sex determination, 1200-1210
- PRL, *see* Plasma prolactin levels
- Progesterone, 1162, 1168, 1305
receptors, 1291
secretion, 1285
- Progressive systemic sclerosis, *see also* Scleroderma
cardiopulmonary manifestations of, 518-522
conduction disturbances and arrhythmias in, 599-600
fibronectin in, 983-986
pulmonary vascular dynamics in, 604
radiographic joint findings in, 595
scleroderma-like syndrome in, 904-910
- Progressive systemic sclerosis (continued)*
skin biopsies in, 132-133
skin thickness vs. collagen content of, 130-140
stages in, 130-131
syndrome resembling, 904-910
- Propranolol, in scleroderma, 1133
- Propionibacterium acnes*, 969
- Propionibacterium granulosum*, 971, 975
- Propionibacterium parvum*, 971, 974-975
- Propionibacterium polysaccharides*, 969-976
- Propylthiouracil, vasculitis associated with, 925-928
- Prostaglandin E₂, in protein and collagen synthesis, 604
- Prostaglandins**
and aspirin, 1109, 1114, 1120
and cartilage degradation 1119-1120
and chloroquine in articular cartilage, 1117-1121
and indomethacin, 1109, 1114, 1120
role in arthritis, 1365
synthesis of, 650, 673
- Prosthetic replacement, radionuclide imaging in, 601
- Protein synthesis**
inhibitors of, 758, 1248
Thiotepa in, 583
- Proteinuria**
as complication of oral gold, 1417-1418
chrysotherapy and, 498
in New Zealand mice, 414
in RA and osteoarthritis, 667
ribavirin and, 147-148
in SLE, 452
- Proteoglycan aggregation**
deficit in, 508-517
disturbance of, 161
- Proteoglycan concentration, guanidine HCl and**, 158
- Proteoglycan degradation, estrogen and**, 57
- Proteoglycan-hyaluronic acid interaction**, 514
- Proteoglycan metabolism**
glycosaminoglycans in, 746
salicylate effect in, 746-753
- Proteoglycan release**
gold sodium thiomalate in, 879
hydrocortisone in, 878, 881
indomethacin in, 878, 881
- Proteoglycan subunits, immunohistochemical localization of**, 647
- Proteoglycan synthesis**, 161
dibutyl-cyclic AMP and, 662
- Proteoglycans**
cartilage, *see* Cartilage proteoglycans
in culture medium and extracts, 513-514
distribution profiles for, 159
metabolism of, 512
neutral protease action in, 655
sequential extraction from cartilage, 512
subunit subpopulations and, 160
- Proteus mirabilis*, 1040
- Protoporphyrin, 1191
- Provera in hereditary angioedema, 1297
- Pseudochyloous effusions, 186
- Pseudogout**
colchicine and, 427

Pseudogout (continued)

- CPPD crystals in, 428
- relative frequency or incidence of, 428
- Pseudogouty arthritis in hypothyroidism, 1416-1417
- Pseudohermaphroditism, male, 1202
- Pseudomonas aeruginosa*, 1040
- Pseudopodagra, from *Hemophilus influenza*, 681-683
- Pseudotumor cerebri, in hypocomplementemic urticarial vasculitis, 1024-1028
- Pseudovaginal perineoscrotal hypospadias, 1280
- Psoriatic arthritis, 243
 - granulocytosis in, 657
 - HLA antigens in, 610
 - morphology of synovial tissue, 1420
 - oral Methotrexate in, 615-616
 - oxygen generation in, 658
 - study of 100 patients with, 656
 - T lymphocytes in, 978-981
- Psoriatic arthropathy, in monozygotic twins, 805-806
- PSS, *see* Progressive systemic sclerosis
- Psychiatric dysfunction in SLE, 1383-1384
- Psychosis, brain reactivity and, 317
- Pulmonary vascular dynamics, abnormalities of, 604
- Purified protein derivative (PPD) response to sex steroids, 1220
- Purine catabolism, block in, 526
- Purine nucleoside phosphorylase, 524-530
- Purine nucleotide degradation, 524
- Pyroglobulin, rheumatoid factor and, 100
- Pyrophosphate
 - biologic variables in measurement of, 892-894
 - in calcium pyrophosphate dihydrate crystal deposition disease, 886-894
 - extrusion of by hyaline and fibrocartilage, 653
- Pyrophosphate quantification, variables in, 654
- Pyrophosphoric acid, 341

R

- Rabbit articular cartilage, nitrogen mustard metabolic effects in, 579-585
- Rabbit auricular cartilage, matrix proteoglycan digestion and, 363
- Rabbit embryo, 1275-1277
- Rabbit osteoarthritis, cartilage proteoglycan alterations in, 155-162
- Radial immunodiffusion, IgG concentration and, 141
- Radioactivity, showing IgM and IgG peaks, 1163
- Radioiodinated human serum albumin, urate in uptake of, 730-731
- Radiologic evaluation, of streptococcus-induced arthritis in rats, 25-35
- Radionuclide uptake, in RA, 651
- Radiotherapy, in mycosis fungoides arthritis, 424-425
- Raji cell radioimmunoassay, 433-438, 440-447, 487, 1021
 - in MCTD, 484
 - in mixed cryoglobulinemia, 1009
 - in progressive systemic sclerosis, 521
- Rat adjuvant arthritis, 334-339
- Rat arthritis
 - collagen-induced, 347-352
 - "pannus" formation in, 35
 - streptococcus-induced, 25-35
 - synovitis in, 34-35
 - vitreal collagen, and 347
- Rauscher murine leukemia virus, 845
- Raynaud's phenomenon
 - ARA criteria for, 817-818
 - in black patients, 817-818
 - corticosteroid therapy in, 817-818
 - progressive systemic sclerosis and, 521
 - in SLE, 815-818, 921
 - Sm antibodies in, 1334-1337
 - skin thickening and, 135-139
- RBAF, *see* Rheumatoid biologically active factor
- RC-RA, *see* Raji cell radioimmunoassay
- Rebound, antibody, 1149
- Receptor number in stimulated cells, 1250-1251
- Receptor-steroid complex, 1290-1291
- Recessive inheritance of H-Y and testis-determining genes, 1204-1206
- Reciprocal hybrids, 1191, 1193
- 5 α -Reduced androgens, 1288
- 5 α -Reductase, 1280-1281, 1288
- Reifenstein syndrome, 1281, 1282
- Reiter's syndrome
 - after salmonella infection, 1141-1142
 - complement levels in, 243-244
 - definition of, 1141-1142
 - epidemic shigellosis and, 659-660
 - HLA-D locus typing in, 371-374
 - sacroiliitis and, 373
- Rejection of fetus by mother, 1300
- Relapsing polychondritis, 204
- Renal abnormalities, in SLE, 452-453
- Renal cortex, gamma globulin elution from, 858-860
- Renal disease, immune, *see* Immune renal disease; *see also* Kidney
- Renal failure, aspirin and ibuprofen associated with, 281-284
- Renal function, depression of in SLE, 629
- Renal histopathology, 1166
- Renal involvement, in scleroderma, management of, 1132-1134
- Renoir, Auguste, 1044-1045, 1047
- Research support for arthritis, 1049-1052
- Respiration, inhibitors of, 758
- Resurfacing, joint, 1093, 1102
- Reticuloendothelial system Fc receptor function, in MCTD, 618
- Retinal toxicity, of hydroxychloroquine, 834-835
- Retrovirus-associated antigens, 1308
- Reverse transcriptase (RT) assays, 845, 850, 855, 1308, 1310, 1312
- Revertant mutation in variant Daudi cells, 1213-1214
- Rheumatic disease
 - T lymphocyte subpopulations in, 978-981
 - uniform database for, 1029-1033
- Rheumatic disease clinics, time-oriented summary medical records in, 673
- Rheumatic Diseases Unit Gold Therapy Clinic, 495
- Rheumatism, nonarticular, 396-399
- Rheumatism Reviews, 1053
- Rheumatoid arthritis
 - alpha-1-antitrypsin phenotypes in, 111-112
 - amyloidosis and, 182-186
 - and ankylosing spondylitis in same family, 203-204
 - antibody-dependent cell-mediated cytotoxicity by monocytes in, 490-493
 - antiglobulin complexes from, 896
 - ¹²⁵I-C1q binding assay in, 440-447
 - cardiac involvement in, 561-564
 - cartilage breakdown in, 877-884
 - cell-mediated collagen immunity in, 665
 - cervical fusions in, 600

Rheumatoid arthritis (continued)

cholesterol crystals in, 186
chrysotherapy in, 105-110, 423
chylous effusions and, 182-186
correlation of disease activity in, 588
correlation of sera and synovial fluid immune complexes in, 443-444
cytotoxic therapy in, 608
defective monocyte toxicity in, 591
and degenerative arthritis, 243-249
diagnosis of, 430
diagnostic criteria in, 84-85
disability in, 676
educational format in, 787-791
familial, 592-593
Felty's syndrome in, 999-1003
gastrointestinal lesions vs. type of aspirin in, 623
glass adherent and prostaglandin producing suppressor cells in, 614
glomerulonephritis in, 1018-1022
gold and antimalarials in, 630
gold therapy in, *see* Chrysotherapy; Gold; Gold sodium thiomalate
gout coexistent with, 81-86, 934-940
group counseling in, 626
hemiparesis effect on, 1419-1420
hyperplasia in, 693
IgG and IgM rheumatoid factors in, 988-997
immune complexes in, 440-447
immune system activity in, 490
immunoassays for immune complexes in, 433-438
knee surgery in, 880
lymphapheresis for, 1055-1059
lymphocyte depletion in, 626-627
MCTD and, 49
MKL/1 mouse as model of, 1080
monoclonal rheumatoid factor binding assay in, 440-447
oral gold compounds, reversible proteinuria and, 1417-1418
oral gold in, 922-925, *see also* Chrysotherapy; Gold
oral Methotrexate in, 615-616
penicillamine and, 197-198, 646
plasmapheresis and lymphoplasmapheresis in management of, 670, 703-709, 1146-1150
platelet aggregation in, 96-902
predictors of medical intervention in, 100
proteinuria in, 667
proteoglycan and collagen degradation in, 664
pyroglobulin in, 100
radionuclide uptake in, 651
Raji cell immunoassay in, 440-447
regional lymphoid irradiation in, 632
relationship to collagen-induced arthritis in animals, 1350
salicylates in, 384-387
septal perforation with saddle-nose deformity in, 101-102
seropositive, 648, 988-997
sicca syndrome and, 640
similarity to mycoplasma-induced arthritis, 1376
spontaneous remission of, 107-108
sulfhydryl inhibitor in, 610
suppressor T cell dysfunction in, 586
synovial permeability in, 689-695
tarsal tunnel syndrome in, 78
thiopronine therapy in, 803-804
thoracic duct drainage in, 1405-1412
tritiated water and, 693

Rheumatoid Arthritis and Related Conditions, book review, 1423

Rheumatoid arthritis synovial membrane, lymphoblastoid cell lines from, 643-644
Rheumatoid biologically active factor, 447, *see also* Rheumatoid factor
Rheumatoid bursitis, of shoulder, 310
Rheumatoid factor
 activity of, 1304
 antiglobulins and, 898
 IgG, *see* IgG rheumatoid factor
 lymphoplasmapheresis and, 705
 in MCTD, 48-50
 and plasmapheresis, 1149
 susceptibility to, 646
 vasculitis and, 926
Rheumatoid fibroblastic cells, GAG synthesis by, 871-876
Rheumatoid lymphoid cells, Epstein-Barr virus transformation of, 605
Rheumatoid sera, antinuclear antibodies in, 667
Rheumatoid synovial effusions, antigenic bacterial polysaccharide in, 969-976
Rheumatoid vasculitis,
 IgG rheumatoid factor and, 995
 plasmapheresis therapy for, 1146-1150
Rheumatologic practices, in U.S., 607
Rheumatologists
 median age of, 188
 training of in U.S., 187-196
Rheumatology
 achievements in, 1041-1054
 and art, 1041-1054
 problems in, 1041-1054
 student's required knowledge of, 290-293
Ribavirin
 body weight and, 148-149
 cyclophosphamide and, 149
 defined, 145-146
 in murine autoimmune disease, 145-152
 proteinuria and, 147-148
 serum immunoglobulin levels and, 149
 SLE in, 152
Ribonuclease-sensitive component, antibodies to, 557
Ribonucleoprotein, antibodies to, 87-92, 557
Ritchie-Camp articular index, 1056
R-MuLV, *see* Rauscher immune leukemia virus
RNA synthesis inhibitors, 1248
RNP antibodies, association with mixed connective tissue disease, 1334
Rochester (Minn.), ankylosing spondylitis epidemiology in, 365-369
Rosette-forming cells, *see* Sheep erythrocyte rosette forming cells
r-RNP, *see* Ribosomal ribonucleoprotein
RT, *see* Reverse transcriptase
Rubella arthritis
 rubella hemagglutination inhibition antibody responses to, 400-402
 vaccine-induced, 400-402

S

SAA, *see* Serum amyloid A protein
Sabin-Feldman toxoplasma antibody, 211-212
Sacroiliac joint, quantitative scintigraphy of, 837-843

- Sacroiliitis, 837
- ankylosing spondylitis and, 303-304
 - radiographs in diagnosis of, 671, 837
 - Reiter's syndrome and, 373
- Saddle-nose deficiency, in RA, 101-102
- Safranin-O
- cartilage staining with, 57-58, 511
 - proteoglycan staining with, 67
- Salicylates, *see also* Aspirin
- as antiinflammatory drug, 384
 - urate excretion and, 605-606
- Salicylate serum half-life, 384
- fluctuation in, 387
- Salicylate therapy
- in Kawasaki syndrome, 621
 - pharmacokinetic monitoring of in children, 826-830
 - in RA, 384-387
- Salmonella enteritidis*, and Reiter's syndrome, 1141-1142
- Sarcoid dacrylitis, 1403-1404
- Sarcoma in New Zealand mice, 1340
- Scintigraphy
- of sacroiliac joint, 837-843
 - salivary, 809-814
- Sclerodactyly, prevalence of antibodies in, 1335
- Scleroderma, *see also* Progressive systemic sclerosis
- antihypertensive management of, 1132-1134
 - antinuclear antibodies in, 640
 - autonephrectomy in, 305
 - circumscribed, 137
 - collagen accumulation in, 627
 - following cosmetic surgery, 532-536
 - gastrointestinal system and, 429
 - in human adjuvant disease, 535
 - localized, 135-137
 - model of, 904-910
 - renal involvement in, 1132-1134
 - Sjögren-like syndrome and, 536
 - skin thickness vs. collagen content in, 130-140
 - Type III collagen in, 609
- Secondary sex differentiation, 1202
- Secondary sex ratio of offspring and HBV infection in parents, 1264-1266
- Secondary syphilis, *see also* Syphilis
- musculoskeletal manifestations of, 174-175
 - synovial fluid studies in, 172-173
- Self-antigens in SLE, 114
- Seminal vesicle, response to testosterone, 1223
- Separation of maternal and fetal circulation, 1301
- Septic bursitis, antibiotic therapy in, 622
- see also* Bursitis
- Septic monarthritis, due to *Listeria monocytogenes*, 1139-1140
- Serologic assay for H-Y antigen, 1200-1201
- Serum, normal human, 220-224, 444
- Serum albumin, *see also* Albumin
- hereditary deficiency of, 738
 - urate binding to, 735-738
- Serum amyloid A protein in amyloidosis and related diseases, 36-41
- Serum complement abnormalities, in childhood SLE, 954-958
- Serum estrone levels, 1285
- Serum salicylate concentrations, fluctuations of, 386-387
- Serum sex hormone binding globulin (SHBG), 1284, 1286, 1289-1290
- Serum steroid binding proteins, 1290
- Serum suppressor substance, 1302
- Self-association, of IgG-rheumatoid factors, 642
- Sex differences
- androgen sensitivity and immune response, 1218-1233
 - in response to hepatitis B virus, 1258-1273
- Sex differentiation, phenotypic, 1275-1284
- Sex factors and autoimmunity, 1161-1198
- Sex hormone binding globulin, 1284, 1289
- Sex hormones, 1186
- and autoantibodies in systemic lupus erythematosus, 1195
 - effect on autoantibodies, 1175-1176
 - effect on autosomal and X-linked genetic control of antibodies, 1177-1187
 - effect of complement-related hereditary angioedema, 1295-1299
 - endocrinology, 1173
 - and immune responses, 1171-1172
 - modulation of autoimmunity in New Zealand mice, 1162-1169
 - pregnancy and immune response, 1274-1313
 - production and action, 1284-1294
 - role in autoimmunity, 1170-1176
- Sex ratio effects, 1267
- Sex ratios in chronic liver disease, 1258
- Sex reversal, 1203-1205
- Sex steroids
- effect on lymphomyeloid system, 1220-1221
 - effect on PPD response, 1220
 - influence on thymic function, 1292
 - transport and mechanism of action of, 1289-1291
- Shakespeare, William, 1043-1044
- SHBG, *see* Serum sex hormone binding globulin
- Sheep joints, and prolonged walking on concrete, 649
- Shoveling, hip injury from, 940-941
- Side-chain cleavage reaction, 1277
- Single-stranded DNA (ssDNA), 1171, 1177, 1180
- Sicca complex, in Sjögren's syndrome, 809
- Sicca syndrome, *see also* Sjögren's syndrome
- primary amyloidosis and, 932-934
 - RA and, 640
 - SLE and, 935-936
- Sickle cell anemia, SLE and, 611, 803
- Simian sarcoma virus, 845
- Sjögren's syndrome, *see also* Sicca syndrome
- abnormalities of in SLE, 641
 - amyloidosis and, 932-934
 - antigen-antibody systems in, 796-798
 - cryoglobulins and, 522
 - defined, 809
 - HLA-B8 antigen in, 373
 - immunoblastic sarcoma and, 911-915
 - inflammation in, 811
 - intermediate complexes in, 141
 - salivary scintigraphy in, 809-814
 - scleroderma and, 536
 - SLE and, 913-915
 - synovitis and, 211
- Skin, immunologic studies of in SLE, 864-869
- Skin biopsies, in progressive systemic sclerosis, 132-134
- Skin changes, in bone marrow transplants, 904-910
- Skin grafts, 1305
- H-Y antigen and, 1200

- Skin thickening**
 collagen content and, 130-140
 in eosinophilic fasciitis, 135-136
 in Raynaud's phenomenon, 137
 reversibility of, 135
- Skn gene**, 1154
- SL/Ni mice**, 1243
- Sm antibody**, 672
 characteristics of, 1336
 frequency in Raynaud's phenomenon, 1334-1337
 in SLE, 1334-1337
- Small bowel bypass, arthritis following**, 711-717
- Specificities, molecular**, 1157
- Sperm cytotoxicity test**, 1201
- Sperry's markers**, 1156
- Spinal ossification, in Forestier's disease**, 799
- Spirochetes, osmiophilic**, 174
- Spiroplasmas, cultivation**, 1379
- Spleen**
 estrogen effects on, 1235
 and IUdR, 1238
 and NK cells, 1239
- Spleen cells**, 1191-1193
- Splenectomy**
 in a lupus antibody syndrome, 1397-1398
 SLE remission, 1397-1398
- Splenomegaly**, 1185
- Sprague-Dawley rats, streptococcus-induced arthritis in**, 25-35
- SS, see Sjögren's syndrome, Sicca syndrome**
- ssDNA, see Single-stranded DNA**
- Stamps, arthritis displayed on**, 538-541
- Staphylococcus aureus**, 732
- Staphylococcus, urate in leukocyte removal and killing of**, 731
- Staphylococcus infection in bursa**, 1362
- State arthritis programs**, 1050
- Stein-Levinthal syndrome**, 1286
- Steroid binding affinity**, 1291
 and metabolic clearance rates, 1289
- Steroid hormone, see also Hormone**
 biosynthesis, 1277
 receptors, 1290-1291
- Steroid receptor proteins**, 1292
- Steroid therapy, see Corticosteroid therapy**
- Still's disease**
 liver failure in, 590
 Takayasu's arteritis and, 684-685, 1422
- Storage of articular cartilage**, 1093-1108
- "Strawberry tongue," in polyarteritis nodosa**, 822
- Streptococcal mucopeptide, antibodies to**, 648
- Streptococcus haemolyticus**, 81
- Stress, glucocorticoids in**, 1247
- ⁹⁰Strontium**, 1238
- Subacute cutaneous lupus erythematosus**, 660
 see also Systemic lupus erythematosus
- Subacute dactylitis**, 1403, 1404
- Subcutaneous bursae, reaction of to disease stimuli**, 597
- Sudeck's atrophy**, 177
- SudSal concentrations, in glycosaminoglycan catabolism**, 749-753
- Sulfate incorporation, estradiol suppression of**, 55-56
- Sulfhydryl inhibitor**, 610
- Superoxide, polymorphonuclear leukocytes and**, 251
- Superoxide anion**, 251
- Superoxide dismutase**
 in collagen gelation, 252
 in superoxide generation, 761
- Superoxide radicals**
 chemotactic factor-induced generation of by neutrophils, 755-761
 defined, 251
 mannitol and, 255
- Suppressor T cells, see T cells**
- Surface-bound immune complexes, human monocytes and**, 649
- Surface fibroblast antigen**, 983, see also Fibronectin
- Surface phenotypes**, 1154-1155
- SV, see Seminal vesicle**
- Swiss cheese cartilage syndrome, see Kniest syndrome**
- Synctiotrophoblast cells**, 1301, 1303
- Synovial biopsies, spirochete-like bodies in**, 175
- Synovial cell DNA synthesis**, 266-267
- Synovial cells, activation of with lymphocytes**, 260-261
- Synovial fat necrosis, in ischemic pancreatic disease**, 547-553
- Synovial fluid**
 hydroxyapatite crystals in, 389-394
 IgG-RF complexes in, 701
 immune complexes in, 440-447
 in jejunoileal bypass, 713
 in secondary syphilis, 172-173
- Synovial fluid analysis, in MCTD**, 48
- Synovial fluid globulin, in synovial fluid C3 immunoelectrophoretic assay**, 243-249
- Synovial fluid glycoproteins, articular cartilage lubrication by**, 665-666
- Synovial fluid leukocytes, antigens of**, 969
- Synovial fluid monocytois**, 294-300
- Synovial membrane, secondary syphilis and**, 175
- Synovial permeability**
 to benzyl alcohol, 694
 in RA, 689-695
- Synovial tissue**
 in vitro studies of, 73
 morphology in psoriatic arthritis, 1420
 restriction of to monoclonal IgG, 622-623
 rubella infection and, 400-402
- Synovium, as "dialysis membrane,"** 692
- Synovium-stimulated cartilage breakdown**, 877-884
- Synovitis**
 following kidney transplantation, 167-168
 in MCTD, 44
 plant thorn, 1037-1038
 in secondary syphilis, 170-176
 reduction in hemiparesis, 1419-1420
- Syphilis, secondary**, 170-176
- Systemic lupus erythematosus (SLE), see also Central nervous system**
 lupus erythematosus; LE cells; Lupus glomerulonephritis
 alopecia in, 921
 alpha-1-antitrypsin phenotypes in, 111-112
 amyloidosis and, 554-556
 anorexia and, 963
 antibodies in cold-reactive lymphocytotoxic, 1060-1063
 antibodies to Sm antigen in 672, 1334-1337
 antibody antinuclear test in, 948
 antibody deposition to cytoplasmic antigen in, 858-862
 antibody syndrome and hypernephroma, 1396-1398
 anti-CNS antibodies in, 1382
 anti-dsDNA and complement profiles in, 226-234

Systemic lupus erythematosus (continued)

- anti-dsDNA specificity for, 229-230
- antigen-antibody systems in, 796-798
- antilymphocyte antibody in, 666
- anti-native DNA detection in, 321-326
- anti-neuroblastoma antibodies in, 460
- and antineural antibodies in CSF, 674
- antineural antibody cross-reactions with erythrocytes and lymphocytes in, 313-319
- antinuclear antibody-positive relations in, 633-634, 674
- antinuclear-antilymphocyte antibody cross-reactivity in, 657
- antiribosomal antibodies in sera of, 463-469
- anti-T cell antibodies and T cells in, 114-121
- aspirin and ibuprofen and acute renal failure in, 281-284
- azathioprine complications in, 937-939
- B and non-B/non-T lymphocytes in, 3-4
- β -1H globulin in, 13-17
- brain disorders accompanying, 317-319
- brain tissue injury in, 461-462
- C3 in dermal-epidermal junction in, 13-17
- C3b-B1H interaction in, 16
- C5 in, 646
- C-reactive protein and infection in, 1421
- central nervous system involvement in, 449-456, 1334-1337
- cerebrospinal fluid C-GMP concentrates in, 450-452
- chemotactic activity in, 1326-1333
- childhood, 669, 954-958
- circulating DNA in, 664
- classification criteria for, 917-921
- CNS
 - cerebrospinal fluid abnormalities, 1382
 - classification of, 1382-1385
 - radiologic abnormalities in, 1382-1383
 - seizures, clinical circumstances of, 1383
- cold-reactive lymphocytotoxic antibodies in, 1060-1063
- complement abnormalities in, 1009-1010
- complement-fixing antibodies to DNA in, 565-570
- corticosteroid-induced renal function depression in, 629
- corticosteroid therapy in, 766, 945-951
- criteria for diagnosis, 917-921, 937, 948
- cryoglobulins in, 305-306
- CSF abnormalities in, 451-452
- cyclic GMP in, 449
- depressed T cell colony growth in, 594
- dermal-epidermal junction deposits in, 652
- diagnosis in, 430
- DNA antibodies in, 1334-1337
- drug-induced, 777, 1060-1063
- Epstein-Barr virus in, 845-855
- erythrocyte inhibition assay for lymphocytotoxic antibodies in, 1064-1073
- estrogen metabolism alterations in, 633, 1195, 1198
- etiology of, 845
- Factor XIa anticoagulant, 1135, 1138
- Factor XII deficiency in, 419-421
- female predominance in, 429
- frequency among Hawaiian ethnic groups, 328-332
- glass adherent and prostaglandin-producing suppressor cells in, 614-615
- glomerular immune complexes in, 632
- glomerulonephritis and, 1018-1022
- deaths in, 764-768

Systemic lupus erythematosus (continued)

- Sm antigens in, 1334-1337
- hemoflagellate kinetoplasts in diagnosis of, 205-207
- HLA-B27 antigen in, 555
- hydroxylation in, 1198
- idiopathic, 305
- IgG anti-brain antibodies in, 674
- immune complexes in CSF and, 658
- immune complex release in, 639
- immune functions in, 770-775
- immunoblastic sarcoma and, 911-915
- immunogenetic factors in, 94
- infection in, 1326-1333
- prevention, 1321-1325
- JRA and, 505, 602-603
- Klinefelter's syndrome in, 1198
- late onset, 590, 674
- Leishmania* organisms in diagnosis of, 205-206
- low avidity anti-DNA antibodies in, 219-224
- low complement levels, in, 231-232
- as lymphocyte dysfunction, 63
- lymphocytotoxic antibodies in, 460
- in male humans, 624
- manifestations of, 921
- measurement of dsDNA antibodies in, 1413-1415
- methylprednisolone pulse therapy in, 629
- mitogen-induced cellular activity inhibiting factor in, 62-63
- mixed connective tissue disease in, 43, 488
- mortality in, 765-766
- multicenter study of survival in, 613
- myocardial infarction and, 764
- native DNA antibodies in, 959-966
- nephritis in, 959-960, *see also* Lupus nephritis
- neurologic events in, 1382-1384
- neuronal cytoplasmic reactivity in, 318
- non-T cell abnormalities in, 773-775
- null cell in, 4
- pancytopenia and, 963
- penicillamine and, 197
- phytohemagglutinin-induced cellular toxicity in, 59-64
- pneumococcal polysaccharide vaccine, effects on 1321-1325
- precipitating antibody to antigen in, 87-92
- procainamide-induced, 305-306
- psychiatric dysfunction in, 1383-1384
- Raynaud's phenomenon and, 815-818
- reduced T lymphocyte purine nucleoside phosphorylase in, 634
- remission after splenectomy, 1397-1398
- renal abnormalities in, 452-453
- renal dialysis in, 591
- ribosomal ribonucleoprotein in, 87-90
- ribavirin and, 152
- self-antigens in, 114
- sepsis in, 767
- serologic abnormalities in, 452
- serum C-reactive protein elevation in, 7-11
- sicca symptoms in, 935-936
- sickle cell anemia and, 803
- sickle hemoglobin in, 611
- Sjögren's syndrome and, 641, 913-915
- skin-kidney immunologic studies in, 864-869
- slow acetylation phenotype in, 95-96
- Sm antibodies in, 672, 1334-1337

Systemic lupus erythematosus (continued)

- spontaneous, 777-779
 - steroid therapy in, 635
 - subnormal circulating lymphocytes in, 118-119
 - survival rate, improvement in, 949-950
 - T-B communication defects in, 655
 - T cell subpopulation alternates in, 3-5
 - thrombocytopenia and, 452
 - T lymphocytes in, 116-118, 594
 - T_γ lymphocytes in, 1-5, 116-117
 - T_{non-γ} lymphocytes in, 3, 773
 - T lymphocytotoxic autoantibody specificity and titer in, 125
 - T lymphocytopenia in, 4
 - Trypanosoma* organisms in, 205-206
 - in twins, 771-773
 - Type C oncornaviruses in, 845-855
 - vs. urticarial vasculitis syndrome, 1027
 - vascular phenomena in, 767-768
- Systemic sclerosis, hyperglobulinemia in, 623

T

- T cell autoantibody, in SLE, 123-128
- T cell colony growth, in SLE, 594
- T cell growth factor, 1246, 1248, 1250, 1252, 1253
- T cell lymphoma, mycosis fungoides as, 424
- T cell purine nucleoside phosphorylase in SLE, 634
- T cell subpopulations, in rheumatic disease, 978-981
- T cells
 - in ADCC activity, 981
 - antibodies to, 1064-1065, 1070-1071
 - blastogenesis, 1246
 - differential sensitivity to T lymphocytotoxic autoantibody in SLE, 123-128
 - effect of estradiol on, 1238
 - graft rejection as response to, 1269
 - immunity, 1238
 - in JRA, 595
 - maternal, 1302
 - natural cytotoxic antibodies to, 127-128
 - and pregnancy, 1219
 - in progressive systemic sclerosis, 131
 - in RA, 586
 - regulation by mononuclear phagocytes, 1352
- T_γ cells, in SLE, 1-5, 116-117
- T_{non-γ} cells, in SLE, 3, 773
- T lymphocytes, *see* T cells
- T lymphocytopenia, in SLE, 4
- T lymphocytotoxic autoantibody, and Con A-activated suppressor T cells, 123-128
- Takayasu's arteritis, Still's disease and, 684-688, 1422
- Tandem duplication, 1157
- Target cells, androgens in, 1279
- Target tissues, 1290-1291
- Tarsal tunnel syndrome, with ankylosing spondylitis, 77-79
- TDD, *see* thoracic duct drainage
- Teaching program, rheumatology in, 290-294
- Temperature, effect on hormones, 1249
- Tendinitis, flexor carpi ulnaris and, 97
- Tenosynovial hand infection from *Mycobacterium terrae* 1386-1389
- Tenosynovitis, 171
- Teslac, *see* Testolactone

- Test, celite eluate, 1136
- Testes
 - estradiol secretion by, 1282
 - histologic differentiation of, 1277
 - 3-hydroxysteroid dehydrogenase synthesis in, 1277
 - mammalian, and H-Y antigen, 1200-1210
 - secretion of DHT, A, and DHEA by, 1288
- Testicular feminization syndrome, 1207, 1281-1283, 1291
- Testicular localization, 1263
- Testicular organogenesis, 1208, 1211
- Testicular transformation, 1211
- Testolactone, 1288
- Testosterone, 1162, 1170-1175, 1185-1186, 1274-1276, 1279, 1288
 - effect on immune response, 1220
 - effect on NTA production, 1184-1185
 - in secondary sex differentiation, 1202
 - seminal vesicle response to, 1223
 - synthesis of, 1277
- Tetraploidization, 1158
- Thermography, in plant thorn synovitis diagnosis, 1037-1038
- Thiopronine therapy, in RA, 803-804
- Thiordazine, 451, 456
- Thiotepa
 - as alkylating agent, 583-585
 - ³H-glycine uptake and, 582
 - intramuscular injections of, 581-582
 - metabolic effects on rabbit articular cartilage and synovium, 579-585
- Thoracic duct drainage in RA, 1405-1412
- Thrombasthenia, Glanzmann's hemarthrosis and 1390-1393
- Thrombocytopenia, in SLE, 452
- Thrombocytopenia purpura, in diffuse eosinophilic fasciitis, 659
- Thy-1 gene, 1154
- Thymectomy
 - effect on ovary, 1243
 - of mice and natural killing levels, 1238
- Thymic function, sex steroid influence, 1292
- Thymocytes, 1154-1155
- Thymocytotoxic autoantibodies, 1191
- Thymosin, 1241
 - fraction 3, 1244
- Thymus, 1174, 1186, 1241, 1243
 - and aging, 1244
 - effect of androgen on, 1229
 - effect of estrogen on, 1235, 1238
 - of rat, 1246
- Thymus cells, 1247-1249
- Thyroid-stimulating hormone (TSH), 1242
- Thyroiditis, induced in rabbits, 1350
- Thyroxine, pseudogout and, 1416-1417
- Ticrynafen, in hyperuricemia or gout, 677
- Tinel's sign, 77
- Tissue hyperoxygenemia, blocking of effective pathways in, 338
- Tissue receptor levels, 1291
- "Total hand" injection, long-term effects of, 619
- Toxoplasma* antibodies, in idiopathic inflammatory muscle disease, 209-214
- Toxoplasma gondii*, antibodies to, 209
- Training, for U.S. rheumatologists, 187-196
- Transdetermination, 1158
- Transmission of HBV from parents to children, 1262
- Transplantation antigen expression of trophoblast, 1301

Transplantation of cartilage, 1093, 1102
 Transport and mechanism of action of sex steroids, 1289-1291
 Trauma, response of superficial bursa to, 1361-1364
Treponema pallidum, 170, 921
 Treponemes, in synovial membrane, 175-176
 Triclinic calcium pyrophosphate dihydrate crystals, *see* Calcium pyrophosphate dihydrate crystals
 Triethylphosphine, in oral gold therapy, 615
 Trochanteric bursitis syndrome, 940
 Trophoblasts, 1310
 and immunoglobulins, 1311-1312
 of placenta, 1308
 transplantation antigen expression on, 1301
Trypanosoma organisms, in SLE diagnosis, 205-206
 TSH, *see* Thyroid-stimulating hormone
 T/t gene, 1154
 Tuberculoid leprosy, 1262-1263
 Tx-3 (C57BL/6Cr \times A/JCr) F₁ female mice, 1242-1243
 Type C oncornaviruses, in SLE, 845-855
 Type C virus, induction of neoplasms in New Zealand mice, 1341
 Type II collagen
 induction of arthritis, 1344-1351
 preparation, 1345
 Type III collagen, in scleroderma skin, 609

U

Ubiquitous expression of H-Y antigen, 1207
 UDPG (uridine diphosphoglucose) pyrophosphorylase method, 886-891
 Uniform Database for Rheumatic Diseases, 1030-1033
 Urate
 albumin and, 734-735
 phlogistic potential of in solution, 728-735
 protein binding of, 737-738
 in removal and killing of staphylococci, 734
 Urate crystals
 complement activator and, 653
 gout diagnosis through, 559-560
 solubility of, 735
 Urate excretion, salicylate and, 605-606
 Urate-induced inflammation, complement depletion and, 571
Uric Acid, book review, 1424
 Uric acid excretion
 fractional 737-738
 in gout, 98-99
 Urticarial vasculitis syndrome, vs. SLE, 1027
 Uterus as privileged immunologic site, 1301-1302

V

Vaccine-induced rubella arthritis, 400-402
 Variant Daudi cell, 1211
 chromosomal characteristics of, 1212
 electrophoresis profile of, 1214

Variant Daudi cell (continued)

 excretion of H-Y antigen, 1214-1215
 HLA expression, 1213-1214
 H-Y antibody absorption capacity of, 1213
 metaphase figure of, 1212
 revertant mutation in, 1213, 1214
 Vasculitis
 in acute monocytic arthritis, 297-298
 hypocomplementemic, 1024-1028
 IgG rheumatoid factor and, 995
 necrotizing and cold-reactive lymphocytotoxic antibodies, 1060-1063
 nonnecrotizing, 298
 platelets and, 901
 propylthiouracil and, 925-928
 in RA, plasmapheresis therapy for, 1146-1150
 Vasopressor excretion, edema and, 396
 Venn diagrams for MCTD sera, 485-487
 Viral arthritis, monocytes in, 301
 Viruses, immune response to, 1257-1273
 Visceral abscess associated with renal failure, cryoglobulins in, 22
 Viscoelastic measurement of articular cartilage, 1103
 Vitamin D metabolites, in oncogenic osteomalacia, 672
 Vitamin E, *see* Alpha-tocopherol
 Vitreous collagen, amino acid composition of, 347
 see also Collagen

W

Weakening of maternal cellular immunity in pregnancy, 1302
 Wistar rats collagen-induced arthritis in, 1344-1351
 Wood lemming, fertile XY females of, 1203-1204
 World Health Organization, 434, 437, 538
 Wrist arthroplasty, cases of, 669
 Wyeth, Andrew, 1046-1047

X

X chromosome, 1202, 1219
 X-labeled hypogammaglobulinemia, chronic polyarthritis and, 71-75
 X-linked and autosomal genetic control of antibodies, effect of sex hormones on, 1177-1187
 X-linked genes, 1172, 1180, 1203
 Xanthine oxidase, 251-252
 in collagen gelation, 254-256
 Xerostomia, 809-812
 XO, *see* Xanthine oxidase
 XX male syndrome, 1202-1203, 1205
 and XX true hermaphroditism, genetic basis in dogs, 1204
 XY gonadal dysgenesis, 1206-1207

Y

Y chromosome, 1193-1194, 1200, 1202-1203
 in accelerated autoimmunity and lymphoproliferation, 1188-1194
 Y-to-autosome translocation, 1204, 1206

